[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 106
1. Jeong WK, Park JW, Choi HS, Chang HJ, Jeong SY: Transanal endoscopic microsurgery for rectal tumors: experience at Korea's National Cancer Center. Surg Endosc; 2009 Nov;23(11):2575-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transanal endoscopic microsurgery for rectal tumors: experience at Korea's National Cancer Center.
  • METHODS: From November 2001 to October 2007, 45 patients underwent TEM for excision of adenoma (13 patients), carcinoid tumor (6 patients), and carcinoma (26 patients).
  • RESULTS: The median tumor distance from the anal verge was 7 cm (range, 3-15 cm), and the median tumor size was 17 mm (range, 2-60 mm).
  • However, one patient with rectal carcinoma died of lung cancer during the follow-up period.
  • Histologic examination of the carcinomas showed pathologic tumor (pT) stage 0 (ypT0) in 2 patients, pT1 in 17 patients (including ypT1 in 1 patient), pT2 in 6 patients, and pT3 in 1 patient.
  • The overall and disease-free 5-year survival rates for patients with carcinoma were 96.2% and 88.5%, respectively.
  • With strict patient selection, it is oncologically safe for early-stage rectal carcinomas.
  • [MeSH-major] Anal Canal / surgery. Microsurgery / methods. Neoplasm Recurrence, Local / pathology. Proctoscopy / methods. Rectal Neoplasms / pathology. Rectal Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenoma / mortality. Adenoma / pathology. Adenoma / surgery. Adult. Aged. Cancer Care Facilities. Carcinoid Tumor / mortality. Carcinoid Tumor / pathology. Carcinoid Tumor / surgery. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Humans. Immunohistochemistry. Intestinal Mucosa / pathology. Intestinal Mucosa / surgery. Korea. Male. Middle Aged. Minimally Invasive Surgical Procedures / adverse effects. Minimally Invasive Surgical Procedures / methods. Neoplasm Staging. Patient Selection. Postoperative Complications / diagnosis. Postoperative Complications / surgery. Reoperation. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2001 Sep;234(3):352-8; discussion 358-9 [11524588.001]
  • [Cites] Br J Surg. 1996 Feb;83(2):207-10 [8689164.001]
  • [Cites] Chirurg. 1984 Oct;55(10):677-80 [6510078.001]
  • [Cites] Anticancer Res. 2004 Mar-Apr;24(2C):1167-72 [15154642.001]
  • [Cites] Dis Colon Rectum. 1991 Oct;34(10):880-5 [1914721.001]
  • [Cites] J Clin Oncol. 1989 Aug;7(8):1003-8 [2754446.001]
  • [Cites] Arch Surg. 1998 Aug;133(8):894-9 [9711965.001]
  • [Cites] Surg Endosc. 2007 Jan;21(1):97-102 [17111281.001]
  • [Cites] Surg Endosc. 2003 Aug;17(8):1283-7 [12739119.001]
  • [Cites] Am J Surg. 2007 Nov;194(5):694-8 [17936438.001]
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):547-56 [16514476.001]
  • [Cites] Dis Colon Rectum. 2008 Jul;51(7):1026-30; discussion 1030-1 [18481147.001]
  • [Cites] Br J Surg. 2005 Dec;92(12):1546-52 [16252312.001]
  • [Cites] Dis Colon Rectum. 1996 Aug;39(8):886-92 [8756844.001]
  • [Cites] Am J Clin Oncol. 1994 Oct;17(5):411-6 [8092113.001]
  • [Cites] Colorectal Dis. 2004 Sep;6(5):350-5 [15335369.001]
  • [Cites] World J Surg. 1992 May-Jun;16(3):437-46 [1317077.001]
  • [Cites] Surg Endosc. 2002 Jun;16(6):989-95 [12163970.001]
  • [Cites] Ann Surg Oncol. 2003 Nov;10(9):1106-11 [14597451.001]
  • [Cites] Surg Endosc. 2007 Jun;21(6):970-4 [17285371.001]
  • [Cites] Br J Surg. 2007 May;94(5):627-33 [17335125.001]
  • [Cites] Dis Colon Rectum. 1996 Sep;39(9):969-76 [8797643.001]
  • [Cites] Dis Colon Rectum. 2000 Aug;43(8):1064-71; discussion 1071-4 [10950004.001]
  • [Cites] Arch Surg. 1998 Jun;133(6):595-8; discussion 598-9 [9637456.001]
  • [Cites] Colorectal Dis. 2006 Sep;8(7):581-5 [16919110.001]
  • [Cites] Dis Colon Rectum. 2005 Feb;48(2):270-84 [15711865.001]
  • (PMID = 19347399.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


2. Zuo ZG, Song HY, Xu C, Li J, Ni SC, Chen SQ: [Combination of trans-anal intersphincteric resection and trans-abdominal total mesorectal excision for anus-retained ultra-low rectal tumors]. Zhonghua Wai Ke Za Zhi; 2009 Jul 1;47(13):988-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combination of trans-anal intersphincteric resection and trans-abdominal total mesorectal excision for anus-retained ultra-low rectal tumors].
  • OBJECTIVE: To study the combination of trans-anal intersphincteric resection and transabdominal total mesorectal excision for anus-retained ultra-low rectal tumors.
  • METHODS: Clinical data of 34 ultra-low rectal tumor patients without external anal sphincter involved, who underwent the combination surgery, were retrospectively analyzed.
  • For pathological types, there were 23 cases of adenocarcinoma (9 well differentiated and 14 moderately differentiated), 1 papillary carcinoma, 2 rectal stromal tumor, 5 rectal villous adenoma with neoplasia and 3 giant villous adenoma.
  • For pathological stages, there were 18 cases at stage pTNM I, 5 at IIA, 1 at IIB, 4 at IIIA, 1 at III and for T grading, there were 15 cases at stage T1, 5 at T2, 8 at T3, 1 at T4.
  • Because of the dysfunction of bowel control, bowel frequency varied from 3 to 12 in the early stage after operation, but with the recovery of anus function, bowel frequency decreased and ranged form 1 to 5 times a day and the time of formed bowel control could be more than 5 min in 6-12 months after operation.
  • However, patients underwent total resection of internal anal sphincter still suffered from incontinence of loose stool after 1 year.
  • CONCLUSION: The combination of trans-anal ISR and trans-abdominal TME for anus-retained ultra low rectal tumor is not only coincident with radical tumor principle but also retains the function of anus, on the premise of the strict indication.
  • [MeSH-major] Anal Canal / surgery. Mesentery / surgery. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19957808.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


3. Fariña-Sarasqueta A, Gosens MJ, Moerland E, van Lijnschoten I, Lemmens VE, Slooter GD, Rutten HJ, van den Brule AJ: TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients. Anal Cell Pathol (Amst); 2010;33(1):1-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients.
  • AIM: Although the predictive and prognostic value of thymidylate synthase (TS) expression and gene polymorphism in colon cancer has been widely studied, the results are inconclusive probably because of methodological differences.
  • With this study, we aimed to elucidate the role of TS gene polymorphisms genotyping in therapy response in stage III colon carcinoma patients treated with 5-FU adjuvant chemotherapy.
  • PATIENTS AND METHODS: 251 patients diagnosed with stage III colon carcinoma treated with surgery followed by 5-FU based adjuvant therapy were selected.
  • RESULTS: There was a positive association between tumor T stage and the VNTR genotypes (p=0.05).In both univariate and multivariate survival analysis no effects of the studied polymorphisms on survival were found.
  • CONCLUSION: We conclude that the TS VNTR and SNP do not predict response to 5-FU therapy in patients with stage III colon carcinoma.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cell Oncol (Dordr). 2011 Aug;34(4):407-8
  • (PMID = 20966539.001).
  • [ISSN] 2210-7185
  • [Journal-full-title] Analytical cellular pathology (Amsterdam)
  • [ISO-abbreviation] Anal Cell Pathol (Amst)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 2.1.1.45 / Thymidylate Synthase; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC4605551
  •  go-up   go-down


Advertisement
4. Koh DM, Dzik-Jurasz A, O'Neill B, Tait D, Husband JE, Brown G: Pelvic phased-array MR imaging of anal carcinoma before and after chemoradiation. Br J Radiol; 2008 Feb;81(962):91-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pelvic phased-array MR imaging of anal carcinoma before and after chemoradiation.
  • The aim of this study was to evaluate the MR findings of anal carcinoma using an external pelvic phased-array coil before and after chemoradiation treatment.
  • 15 patients with carcinoma of the anal canal underwent T(2) weighted and short-tau inversion recovery (STIR) imaging before and after chemoradiation.
  • At pre-treatment imaging, the tumour size and stage, signal intensity and infiltration of adjacent structures were recorded.
  • Pelvic phased-array MR imaging is useful for local staging of anal carcinoma and assessing treatment response.
  • [MeSH-major] Anus Neoplasms / diagnosis. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Magnetic Resonance Imaging

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18238920.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


5. Wang H, Fu CG, Zheng JM, Gong HF, Tao LY, Yu ED, Zhang W, Liu LJ, Hao LQ, Meng RG: [Impact of meticulousness of pathologists on lymph node harvest after radical resection of invasive rectal carcinoma]. Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Nov;12(6):569-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Impact of meticulousness of pathologists on lymph node harvest after radical resection of invasive rectal carcinoma].
  • OBJECTIVE: To analyze the impact of meticulousness of pathologists on the lymph node harvest after radical resection of invasive rectal carcinoma.
  • METHODS: From January 2008 to May 2009, the clinical data of rectal cancer patients undergone operation were reviewed retrospectively.
  • After multidisciplinary cooperation on rectal cancer, a new rule was applied to request the pathologists to find no less than 15 nodes in single colorectal specimen from January 2009.
  • Excluded criteria were recurrent colorectal tumor, Tis tumor, R(1) or R(2) resection, tumor resection transanally or endoscopically, the cases enrolled in other prospective research, synchronous diseases affecting the surgical procedure for the rectal cancer (familial adenomatous polyposis, synchronous colorectal carcinoma) and rectal cancer receiving neoadjuvant chemoradiation.
  • There were no significant differences in gender (46/76 vs 86/156, P=0.436), age (58.1+/-1.3 vs 59.2+/-1.1, P=0.527), distance from tumor to anal verge (7.4+/-0.4 vs 7.1+/-0.3, P=0.761), proportion of sphincter-sparing surgery (67/76 vs 140/156, P=0.715), ratio of well and moderate differentiated tumors (68/76 vs 125/156, P=0.074) and overall TNM stage (P=0.167) between the two groups.
  • The good performance of pathologists could produce adequate number of lymph nodes for rectal cancer without neoadjuvant chemoradiation.

  • MedlinePlus Health Information. consumer health - Biopsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19921565.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


6. Ren N, Ye QH, Qin LX, Zhang BH, Liu YK, Tang ZY: Circulating DNA level is negatively associated with the long-term survival of hepatocellular carcinoma patients. World J Gastroenterol; 2006 Jun 28;12(24):3911-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating DNA level is negatively associated with the long-term survival of hepatocellular carcinoma patients.
  • AIM: To quantify the circulating DNA in plasma from patients with hepatocellular carcinoma (HCC) and to evaluate its prognostic value.
  • The circulating DNA level was closely associated with tumor size (P = 0.008) and TNM stage (P = 0.040), negatively associated with the 3-year disease-free survival (DFS) (P = 0.017) and overall survival (OS) (P = 0.001).
  • [MeSH-major] Carcinoma, Hepatocellular / blood. Carcinoma, Hepatocellular / pathology. DNA, Neoplasm / blood. Liver Neoplasms / blood. Liver Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1047-52 [12631605.001]
  • [Cites] Int J Cancer. 2003 Jan 10;103(2):149-52 [12455027.001]
  • [Cites] N Engl J Med. 2004 Jun 10;350(24):2461-70 [15190138.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1022:17-24 [15251934.001]
  • [Cites] Cancer Res. 1977 Mar;37(3):646-50 [837366.001]
  • [Cites] Oncology. 1989;46(5):318-22 [2779946.001]
  • [Cites] Cancer. 1990 Nov 15;66(10):2174-9 [2171748.001]
  • [Cites] Mol Med. 1995 May;1(4):344-65 [8521292.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):578-84 [10080602.001]
  • [Cites] Hepatology. 1999 Oct;30(4):1027-36 [10498656.001]
  • [Cites] Nature. 1953 Apr 25;171(4356):737-8 [13054692.001]
  • [Cites] Anal Biochem. 1999 Dec 1;276(1):59-64 [10585744.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1805-11 [11078757.001]
  • [Cites] Transfusion. 2001 Feb;41(2):276-82 [11239235.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4675-8 [11406535.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5723-6 [11479206.001]
  • [Cites] Clin Chem. 2001 Sep;47(9):1607-13 [11514393.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • [Cites] World J Gastroenterol. 2002 Apr;8(2):193-9 [11925590.001]
  • [Cites] World J Gastroenterol. 2001 Aug;7(4):445-54 [11819809.001]
  • [Cites] Anticancer Res. 2002 Jan-Feb;22(1A):421-5 [12017326.001]
  • [Cites] Br J Cancer. 2002 Dec 2;87(12):1449-53 [12454776.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1579-82 [14571790.001]
  • (PMID = 16804981.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC4087944
  •  go-up   go-down


7. Koksal IT, Ates M, Danisman A, Sezer C, Ciftcioglu A, Karpuzoglu G, Sevuk M: Reduced E-cadherin and alpha-catenin expressions have no prognostic role in bladder carcinoma. Pathol Oncol Res; 2006;12(1):13-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced E-cadherin and alpha-catenin expressions have no prognostic role in bladder carcinoma.
  • We have used immunohistochemistry to localize Ecadherin and alpha-catenin in 56 formalin-fixed, paraffin-embedded tissue blocks from 41 patients with superficial bladder cancer and 15 with invasive bladder cancer.
  • We have demonstrated that abnormal expression of E-cadherin and/or alpha-catenin occurs in more than 85% of bladder carcinomas and correlates significantly only with advanced stage.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1983 Jul;130(1):56-60 [6864915.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):8-31, 1 [10200775.001]
  • [Cites] Eur Urol. 1992;21(3):177-83 [1499624.001]
  • [Cites] J Urol. 1993 May;149(5):957-72 [8483247.001]
  • [Cites] J Urol. 2000 Jan;163(1):73-8 [10604317.001]
  • [Cites] Cell. 1992 Jul 24;70(2):293-301 [1638632.001]
  • [Cites] Cancer. 1992 Aug 15;70(4):799-807 [1643611.001]
  • [Cites] Int J Cancer. 1995 Dec 20;64(6):367-70 [8550236.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4154-8 [8797585.001]
  • [Cites] Hum Pathol. 1995 Sep;26(9):940-4 [7672793.001]
  • [Cites] Cancer Res. 1994 Jun 15;54(12 ):3120-3 [8205527.001]
  • [Cites] J Cancer Res Clin Oncol. 1995;121(5):303-8 [7768969.001]
  • [Cites] Pathology. 2002 Jun;34(3):233-8 [12109783.001]
  • [Cites] Anal Cell Pathol. 1997 May;13(3):125-36 [9223755.001]
  • [Cites] Invasion Metastasis. 1997;17(3):124-37 [9702939.001]
  • [Cites] Cancer Res. 1992 Oct 15;52(20):5770-4 [1394201.001]
  • [Cites] J Urol. 1998 Nov;160(5):1889-93 [9783980.001]
  • [Cites] J Pathol. 1997 Jul;182(3):331-8 [9349237.001]
  • [Cites] Science. 1991 Mar 22;251(5000):1451-5 [2006419.001]
  • [Cites] Br J Urol. 1988 Oct;62(4):339-42 [3191359.001]
  • [Cites] Cancer Res. 1993 Apr 1;53(7):1696-701 [8453644.001]
  • [Cites] Differentiation. 1988 Jun;38(1):67-71 [3263290.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jun;87(11):4246-50 [2349235.001]
  • [Cites] Urol Clin North Am. 1988 Nov;15(4):661-9 [3142129.001]
  • [Cites] World J Urol. 1996;14 Suppl 1:S12-5 [8738404.001]
  • [Cites] Int J Cancer. 1999 Nov 26;83(5):591-5 [10521791.001]
  • [Cites] EMBO J. 1989 Jun;8(6):1711-7 [2788574.001]
  • [Cites] Cancer Metastasis Rev. 1993 Mar;12(1):29-37 [8448824.001]
  • [Cites] Cancer Res. 1993 Jul 15;53(14):3241-5 [8324734.001]
  • (PMID = 16554911.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / alpha Catenin
  •  go-up   go-down


8. Jung M, Ramankulov A, Roigas J, Johannsen M, Ringsdorf M, Kristiansen G, Jung K: In search of suitable reference genes for gene expression studies of human renal cell carcinoma by real-time PCR. BMC Mol Biol; 2007;8:47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In search of suitable reference genes for gene expression studies of human renal cell carcinoma by real-time PCR.
  • No conclusive systematic study comparing the suitability of different candidate reference genes in clear cell renal cell carcinoma has been published to date.
  • RESULTS: The expression of the potential reference genes was examined in matched malignant and non-malignant tissue specimens from 25 patients with clear cell renal cell carcinoma.
  • The expression of all genes did not depend on age, sex, and tumour stage.
  • CONCLUSION: Our study demonstrated the suitability of the two housekeeping genes PPIA and TBP as endogenous reference genes when comparing malignant tissue samples with adjacent normal tissue samples from clear cell renal cell carcinoma.
  • [MeSH-major] Carcinoma, Renal Cell / genetics. Gene Expression Regulation, Neoplastic / genetics. Genes, Neoplasm / genetics. Kidney Neoplasms / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Biochem. 2002 Oct 15;309(2):293-300 [12413463.001]
  • [Cites] Thorax. 2002 Sep;57(9):765-70 [12200519.001]
  • [Cites] Yakugaku Zasshi. 2003 May;123(5):369-75 [12772594.001]
  • [Cites] Kidney Int. 2003 Jul;64(1):356-60 [12787429.001]
  • [Cites] Nat Genet. 2003 Dec;35(4):292-3 [14647279.001]
  • [Cites] Kidney Int. 2004 Jan;65(1):97-105 [14675040.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 23;313(4):856-62 [14706621.001]
  • [Cites] Anal Biochem. 2004 May 15;328(2):101-8 [15113684.001]
  • [Cites] Biotechnol Lett. 2004 Mar;26(6):509-15 [15127793.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5245-50 [15289330.001]
  • [Cites] Genome Biol. 2004;5(8):R59 [15287981.001]
  • [Cites] J Biomol Tech. 2004 Sep;15(3):155-66 [15331581.001]
  • [Cites] J Urol (Paris). 1994;100(4):189-95 [7868931.001]
  • [Cites] Anal Biochem. 2004 Dec 1;335(1):1-9 [15519565.001]
  • [Cites] Mol Diagn. 2004;8(2):107-13 [15527325.001]
  • [Cites] Kidney Int. 2004 Dec;66(6):2308-14 [15569320.001]
  • [Cites] Lab Invest. 2005 Jan;85(1):154-9 [15543203.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):1043-52 [15592504.001]
  • [Cites] Nucleic Acids Res. 2005;33(6):e56 [15800207.001]
  • [Cites] Genes Immun. 2005 Jun;6(4):279-84 [15815687.001]
  • [Cites] J Mol Endocrinol. 2005 Jun;34(3):597-601 [15956331.001]
  • [Cites] Anal Biochem. 2005 Sep 1;344(1):141-3 [16054107.001]
  • [Cites] Biomarkers. 2005 Jul-Aug;10(4):258-94 [16191485.001]
  • [Cites] J Mol Med (Berl). 2005 Dec;83(12):1014-24 [16211407.001]
  • [Cites] BMC Mol Biol. 2006;7:3 [16448564.001]
  • [Cites] J Urol. 2006 May;175(5):1915-20 [16600798.001]
  • [Cites] Eur Urol. 2006 May;49(5):798-805 [16442207.001]
  • [Cites] Int J Urol. 2006 Mar;13(3):265-70 [16643621.001]
  • [Cites] Mar Biotechnol (NY). 2006 Jul-Aug;8(4):398-408 [16676145.001]
  • [Cites] Anal Biochem. 2006 Sep 1;356(1):36-43 [16844072.001]
  • [Cites] BMC Mol Biol. 2006;7:33 [17026756.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] J Biotechnol. 1999 Oct 8;75(2-3):291-5 [10617337.001]
  • [Cites] J Mol Endocrinol. 2000 Oct;25(2):169-93 [11013345.001]
  • [Cites] J Biochem Biophys Methods. 2000 Nov 20;46(1-2):69-81 [11086195.001]
  • [Cites] J Natl Cancer Inst. 2002 Apr 3;94(7):513-21 [11929952.001]
  • [Cites] Anal Biochem. 2002 Apr 15;303(2):209-14 [11950223.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] J Mol Endocrinol. 2002 Aug;29(1):23-39 [12200227.001]
  • [Cites] Physiol Genomics. 2003 Jan 15;12(2):163-74 [12419855.001]
  • (PMID = 17559644.001).
  • [ISSN] 1471-2199
  • [Journal-full-title] BMC molecular biology
  • [ISO-abbreviation] BMC Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Membrane Proteins; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / ADAM9 protein, human
  • [Other-IDs] NLM/ PMC1913536
  •  go-up   go-down


9. Roohipour R, Patil S, Goodman KA, Minsky BD, Wong WD, Guillem JG, Paty PB, Weiser MR, Neuman HB, Shia J, Schrag D, Temple LK: Squamous-cell carcinoma of the anal canal: predictors of treatment outcome. Dis Colon Rectum; 2008 Feb;51(2):147-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous-cell carcinoma of the anal canal: predictors of treatment outcome.
  • PURPOSE: The incidence of anal canal squamous-cell carcinoma is increasing.
  • METHODS: Using one database, we identified 131 Stages I-III patients treated for primary anal canal squamous-cell carcinoma at our institution from December 1986 to August 2006, with minimum six-month follow-up.
  • RESULTS: Of 131 patients (median age, 58.3 years; median follow-up, 2.9 (range, 0.6-11.2) years), 66 percent were females, 43.5 percent were Stage II, and 11 (8 percent) were HIV-positive.
  • Almost all patients undergoing radiotherapy (96.7 percent, 118/122) also had chemotherapy: 118 (100 percent, Stages I-III) had concurrent chemotherapy: (98 (83.8 percent) mitomycin/5-fluorouracil, 12 (10.2 percent) cisplatin/5-fluorouracil, 8 (6.8 percent) 5-fluorouracil alone); 35 of 46 (76 percent) Stage III patients received induction chemotherapy (34 (97.1 percent) cisplatin/5-fluorouracil, 1 (2.8 percent) 5-fluorouracil alone).
  • Many (44 percent Stages I/II, 48.9 percent Stage III) required dose adjustments.
  • Bivariate analyses demonstrated that T stage (P=0.0019), completion of radiotherapy, and total radiotherapy dose (P=0.03) were all significantly associated with treatment failure.
  • On multivariate analyses, disease stage (P=0.05) and completion of radiotherapy (P=0.01) remained significant predictors of relapse-free survival.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Dis Colon Rectum. 2008 May;51(5):620
  • (PMID = 18180997.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


10. Bilimoria KY, Bentrem DJ, Rock CE, Stewart AK, Ko CY, Halverson A: Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base. Dis Colon Rectum; 2009 Apr;52(4):624-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base.
  • PURPOSE: The objective of this study was to assess survival and prognostic factors for anal carcinoma in the population.
  • METHODS: Patients with squamous-cell carcinoma of the anal canal were identified from the National Cancer Data Base (1985-2000).
  • Concordance was calculated to assess agreement between American Joint Committee on Cancer stage and actual outcome.
  • RESULTS: Nineteen thousand one hundred ninety-nine patients with anal carcinoma were identified (Stage I, 25.3 percent; Stage II, 51.8 percent; Stage III, 17.1 percent; Stage IV, 5.7 percent).
  • The American Joint Committee on Cancer (6th edition) staging system provided good survival discrimination by stage: I, 69.5 percent; II, 59.0 percent; III, 40.6 percent; and IV, 18.7 percent (concordance index, 0.663).
  • On multivariable analysis, patients with anal carcinoma had a higher risk of death if they were male, >or=65 years old, black, living in lower median incomes areas, and had more advanced T stage tumors, nodal or distant metastases, or poorly differentiated cancers (P < 0.0001).
  • There was not a significant difference in survival by hospital type or year of diagnosis.
  • CONCLUSION: Although tumor characteristics and staging affect prognosis, patient factors, such as gender, race, and socioeconomic status, are also important prognostic factors for squamous-cell carcinoma of the anal canal.
  • [MeSH-major] Anus Neoplasms / mortality. Carcinoma, Squamous Cell / mortality


11. Wang X, Zheng B, Zhang RR, Li S, Chen X, Mulvihill JJ, Lu X, Pang H, Liu H: Automated analysis of fluorescent in situ hybridization (FISH) labeled genetic biomarkers in assisting cervical cancer diagnosis. Technol Cancer Res Treat; 2010 Jun;9(3):231-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Automated analysis of fluorescent in situ hybridization (FISH) labeled genetic biomarkers in assisting cervical cancer diagnosis.
  • The numerical and/or structural deviation of some chromosomes (i.e., monosomy and _polysomy of chromosomes 3 and X) are routinely used as positive genetic biomarkers to diagnose cervical cancer and predict the disease progression.
  • Among the available diagnostic methods to analyze the aneusomy of chromosomes 3 and X, fluorescence in situ hybridization (FISH) technology has demonstrated significant advantages in assisting clinicians to more accurately detect and diagnose cervical carcinoma at an early stage, in particular for the women at a high risk for progression of low-grade and high-grade squamous intra-epithelium lesions (LSIL and HSIL).
  • In order to increase the diagnostic accuracy, consistency, and efficiency from that of manual FISH analysis, this study aims to develop and test an automated FISH analysis method that includes a two-stage scheme.
  • In the first stage, an interactive multiple-threshold algorithm is utilized to segment potential interphase nuclei candidates distributed in different intensity levels and a rule-based classifier is implemented to identify analyzable interphase cells.
  • In the second stage, FISH labeled biomarker spots of chromosomes 3 and X are segmented by a top-hat transform.
  • The experimental results of four test cases showed high agreement of FISH analysis results between the automated scheme and the cytogeneticist's analysis including 92.7% to 98.7% agreement in cell segmentation and 4.4% to 11.0% difference in cell classification.
  • This preliminary study demonstrates the feasibility of potentially applying the automatic FISH analysis method to expedite the screening and detecting cervical cancer at an early stage.
  • [MeSH-major] Biomarkers, Tumor / analysis. In Situ Hybridization, Fluorescence / methods. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / genetics
  • [MeSH-minor] Automation. Cervical Intraepithelial Neoplasia / diagnosis. Cervical Intraepithelial Neoplasia / genetics. Female. Humans. Vaginal Smears

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2000 Nov;164(5):1768-75 [11025767.001]
  • [Cites] Cytometry. 1997 May 1;28(1):1-10 [9136750.001]
  • [Cites] Int J Cancer. 2001 Feb 1;91(3):359-65 [11169960.001]
  • [Cites] J Natl Cancer Inst. 2002 Jun 5;94(11):852-4 [12048273.001]
  • [Cites] Diagn Cytopathol. 2003 Jun;28(6):301-7 [12768634.001]
  • [Cites] Cancer. 2003 Oct 25;99(5):310-5 [14579298.001]
  • [Cites] Anal Cell Pathol. 1997 May;13(3):137-46 [9223756.001]
  • [Cites] Cytometry. 1997 Aug 1;28(4):289-97 [9266748.001]
  • [Cites] Hum Genet. 1997 Oct;100(5-6):525-35 [9341866.001]
  • [Cites] Blood. 1998 May 1;91(9):3357-65 [9558393.001]
  • [Cites] Cytometry. 1999 Aug 1;36(4):279-93 [10404143.001]
  • [Cites] Gynecol Oncol. 1999 Oct;75(1):41-6 [10502423.001]
  • [Cites] Am J Pathol. 2005 Apr;166(4):1229-38 [15793301.001]
  • [Cites] Am J Clin Pathol. 2005 May;123(5):716-23 [15981811.001]
  • [Cites] Cytometry A. 2005 Sep;67(1):18-26 [16082715.001]
  • [Cites] J Med Virol. 2006 Jan;78(1):117-24 [16299730.001]
  • [Cites] Cytometry A. 2006 Jun;69(6):506-14 [16646048.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3032-8 [16809727.001]
  • [Cites] J Pathol. 2006 Dec;210(4):412-9 [17054308.001]
  • [Cites] Technol Cancer Res Treat. 2008 Jun;7(3):161-74 [18473488.001]
  • [Cites] J Biomed Opt. 2009 Mar-Apr;14(2):021002 [19405715.001]
  • [Cites] Eur J Cancer. 2004 Jul;40(10):1624-9 [15196550.001]
  • [Cites] Pathol Oncol Res. 2004;10(3):142-8 [15448749.001]
  • [Cites] J Natl Cancer Inst. 1994 Jan 5;86(1):6-7 [8271287.001]
  • [Cites] Cytometry. 1996 Jun 1;24(2):158-66 [8725665.001]
  • [Cites] Cytometry. 2001 Feb 1;43(2):87-93 [11169572.001]
  • (PMID = 20441233.001).
  • [ISSN] 1533-0338
  • [Journal-full-title] Technology in cancer research & treatment
  • [ISO-abbreviation] Technol. Cancer Res. Treat.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA136700; United States / NCI NIH HHS / CA / R01 CA136700-01; United States / NCI NIH HHS / CA / CA136700
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS220245; NLM/ PMC2916642
  •  go-up   go-down


12. Vironen J, Juhola M, Kairaluoma M, Jantunen I, Kellokumpu I: Tumour regression grading in the evaluation of tumour response after different preoperative radiotherapy treatments for rectal carcinoma. Int J Colorectal Dis; 2005 Sep;20(5):440-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumour regression grading in the evaluation of tumour response after different preoperative radiotherapy treatments for rectal carcinoma.
  • BACKGROUND AND AIMS: Preoperative radiotherapy (PRT) for rectal carcinoma has been shown to cause tumour regression and increase local control and patient survival.
  • METHODS: Depending on the tumour stage (uT), as defined by preoperative endorectal ultrasound (ERUS), fixity and distance from the anal verge, 126 patients with rectal cancer underwent either surgery alone, or received short-course 25-Gy radiotherapy or long-course 50-Gy radiotherapy combined with 5-fluorouracil (5-FU) before surgery.
  • TRG in each group was assessed and compared with the downstaging, defined as a change in preoperative uT stage and pathologic stage (pT).
  • In contrast, T-stage downstaging was similar in both groups and did not correlate with the TRG results (p=0.05).

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1990 Feb;211(2):187-95 [2405793.001]
  • [Cites] Dis Colon Rectum. 1999 Feb;42(2):159-66 [10211490.001]
  • [Cites] Lancet. 1993 Feb 20;341(8843):457-60 [8094488.001]
  • [Cites] Br J Surg. 2003 Aug;90(8):999-1003 [12905555.001]
  • [Cites] Am J Surg. 1995 Dec;170(6):609-12; discussion 612-3 [7492011.001]
  • [Cites] N Engl J Med. 1997 Apr 3;336(14 ):980-7 [9091798.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):51-7 [9747819.001]
  • [Cites] Ann Surg. 2001 Nov;234(5):633-40 [11685026.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):289-95 [9069299.001]
  • [Cites] Ann Surg. 2002 Jul;236(1):75-81 [12131088.001]
  • [Cites] Dis Colon Rectum. 2003 Mar;46(3):298-304 [12626903.001]
  • [Cites] Int J Colorectal Dis. 1996;11(6):283-6 [9007624.001]
  • [Cites] World J Surg. 2001 Aug;25(8):1006-11 [11571965.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):1976-84 [11283130.001]
  • [Cites] Aust N Z J Surg. 1999 Oct;69(10):737-42 [10527353.001]
  • [Cites] N Engl J Med. 1991 Mar 14;324(11):709-15 [1997835.001]
  • [Cites] World J Surg. 2000 Feb;24(2):208-15 [10633148.001]
  • [Cites] Hum Pathol. 2003 Jun;34(6):541-8 [12827607.001]
  • [Cites] Cancer. 2003 Jan 15;97(2):517-24 [12518377.001]
  • [Cites] Int J Colorectal Dis. 1997;12 (1):19-23 [9112145.001]
  • [Cites] Br J Surg. 1999 Sep;86(9):1108-20 [10504363.001]
  • [Cites] Dis Colon Rectum. 1985 Jan;28(1):42-6 [3882360.001]
  • [Cites] Ann Surg Oncol. 2001 Dec;8(10):801-6 [11776494.001]
  • [Cites] Scand J Surg. 2003;92 (1):25-33 [12705548.001]
  • [Cites] Dis Colon Rectum. 2002 Aug;45(8):1051-6 [12195189.001]
  • [Cites] World J Surg. 1997 Sep;21(7):733-40 [9276705.001]
  • [Cites] Dis Colon Rectum. 2002 Jul;45(7):895-903 [12130878.001]
  • [Cites] Ann Surg Oncol. 2002 Jun;9(5):444-9 [12052754.001]
  • [Cites] Ann Surg. 2002 Aug;236(2):203-7 [12170025.001]
  • (PMID = 15856263.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


13. Tamura Y, Igarashi M, Kawai H, Suda T, Satomura S, Aoyagi Y: Clinical advantage of highly sensitive on-chip immunoassay for fucosylated fraction of alpha-fetoprotein in patients with hepatocellular carcinoma. Dig Dis Sci; 2010 Dec;55(12):3576-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical advantage of highly sensitive on-chip immunoassay for fucosylated fraction of alpha-fetoprotein in patients with hepatocellular carcinoma.
  • BACKGROUND: Alpha-fetoprotein (AFP) has been widely used as a diagnostic master for hepatocellular carcinoma (HCC), and the fucosylated fraction of AFP (AFP-L3) has been reported to be a specific marker for HCC.
  • The positivity rates for μ-TAS AFP-L3 were higher at each tumor stage than those of LiBASys AFP-L3 (μ-TAS/LiBASys: stage I, 44.2%/16.3%; stage II, 52.9%/37.5%; stage III, 66.4%/44.5%; stage IV, 82.8%/65.5%).
  • CONCLUSIONS: μ-TAS AFP-L3 is more sensitive for discriminating HCC than the conventional LiBASys AFP-L3, particularly in subgroups with lower AFP concentrations and early-stage HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Immunoassay / methods. Liver Neoplasms / diagnosis. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Electrophoresis. 2008 Apr;29(7):1399-406 [18384019.001]
  • [Cites] J Gastroenterol Hepatol. 2001 Dec;16(12):1378-83 [11851836.001]
  • [Cites] Am J Gastroenterol. 1999 Oct;94(10):3028-33 [10520864.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2076-82 [9827711.001]
  • [Cites] Hepatology. 1993 Jan;17(1):50-2 [7678576.001]
  • [Cites] J Gastroenterol. 2003;38(3):207-15 [12673442.001]
  • [Cites] Anal Biochem. 2009 May 15;388(2):306-11 [19250915.001]
  • [Cites] Cancer Res. 1968 Jul;28(7):1344-50 [4174340.001]
  • [Cites] Am J Gastroenterol. 1998 Dec;93(12):2452-6 [9860408.001]
  • [Cites] J Gastroenterol. 2007 Dec;42(12):962-8 [18085353.001]
  • [Cites] Cancer Res. 1993 Nov 15;53(22):5419-23 [7693340.001]
  • [Cites] J Hepatol. 1999 Jan;30(1):125-30 [9927159.001]
  • [Cites] Cancer. 1988 Feb 15;61(4):769-74 [2448024.001]
  • [Cites] Cancer. 1970 May;25(5):1091-8 [5443731.001]
  • [Cites] J Clin Gastroenterol. 2001 Mar;32(3):240-4 [11246354.001]
  • [Cites] Hepatology. 2006 Dec;44(6):1518-27 [17133456.001]
  • [Cites] Hepatol Res. 2007 Nov;37(11):914-22 [17610501.001]
  • [Cites] Am J Clin Pathol. 1999 Jun;111(6):811-6 [10361518.001]
  • [Cites] Anal Chem. 1998 Mar 1;70(5):954-7 [9511471.001]
  • (PMID = 20407827.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AFP protein, human; 0 / Plant Lectins; 0 / alpha-Fetoproteins
  •  go-up   go-down


14. Kekatpure VD, Boyle JO, Zhou XK, Duffield-Lillico AJ, Gross ND, Lee NY, Subbaramaiah K, Morrow JD, Milne G, Lippman SM, Dannenberg AJ: Elevated levels of urinary prostaglandin e metabolite indicate a poor prognosis in ever smoker head and neck squamous cell carcinoma patients. Cancer Prev Res (Phila); 2009 Nov;2(11):957-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated levels of urinary prostaglandin e metabolite indicate a poor prognosis in ever smoker head and neck squamous cell carcinoma patients.
  • Cyclooxygenase (COX)-derived prostaglandin E(2) (PGE(2)) plays a role in the development and progression of several tumor types including head and neck squamous cell carcinoma (HNSCC).
  • There were no statistically significant differences between patients with (n = 15) or without disease progression (n = 16) with regard to stage, site, treatment received, smoking status, and aspirin use during follow-up.
  • These differences were most evident among patients with early-stage disease.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2000 Jan 1;164(1):361-70 [10605031.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] Annu Rev Biochem. 2000;69:145-82 [10966456.001]
  • [Cites] Neoplasia. 2001 Jan-Feb;3(1):53-61 [11326316.001]
  • [Cites] J Biol Chem. 2001 May 25;276(21):18075-81 [11278548.001]
  • [Cites] J Biol Chem. 2002 Jan 25;277(4):2614-9 [11706038.001]
  • [Cites] Nat Med. 2002 Mar;8(3):289-93 [11875501.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3395-401 [12067981.001]
  • [Cites] Hum Pathol. 2002 Jul;33(7):708-14 [12196922.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6706-11 [12438270.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):961-8 [12631593.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3425-30 [12960132.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35451-7 [12824187.001]
  • [Cites] J Natl Cancer Inst. 2003 Oct 1;95(19):1440-52 [14519750.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):431-6 [14706335.001]
  • [Cites] Anal Biochem. 2004 Nov 15;334(2):266-75 [15494133.001]
  • [Cites] J Am Chem Soc. 1969 Apr 9;91(8):2177-8 [5784182.001]
  • [Cites] Nature. 1970 Feb 14;225(5233):600-4 [4983971.001]
  • [Cites] J Biol Chem. 1971 Nov 25;246(22):6713-21 [5126221.001]
  • [Cites] Prostaglandins. 1976 Feb;11(2):381-97 [772759.001]
  • [Cites] Gastroenterology. 1978 Oct;75(4):638-40 [30669.001]
  • [Cites] Arch Otolaryngol. 1981 Nov;107(11):658-63 [7295159.001]
  • [Cites] Anal Biochem. 1983 Feb 1;128(2):351-8 [6846812.001]
  • [Cites] Laryngoscope. 1985 Mar;95(3):307-12 [3919231.001]
  • [Cites] J Cancer Res Clin Oncol. 1992;118(4):308-13 [1577849.001]
  • [Cites] J Lab Clin Med. 1993 Nov;122(5):518-23 [8228569.001]
  • [Cites] J Clin Invest. 1994 Feb;93(2):493-8 [8113389.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 1996 Feb;54(2):83-94 [8848435.001]
  • [Cites] Cell. 1996 Nov 29;87(5):803-9 [8945508.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3336-40 [9096394.001]
  • [Cites] J Clin Invest. 1997 May 1;99(9):2254-9 [9151799.001]
  • [Cites] Cancer Res. 1998 Jan 15;58(2):362-6 [9443418.001]
  • [Cites] Cancer Res. 1998 Feb 1;58(3):409-12 [9458081.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1208-16 [9515807.001]
  • [Cites] Cell. 1998 May 29;93(5):705-16 [9630216.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):991-4 [10070952.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):664-70 [15695412.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):6087-93 [16115954.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6634-40 [16166442.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6976-81 [16172459.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):10113-9 [16267038.001]
  • [Cites] J Biol Chem. 2006 Feb 10;281(6):3321-8 [16338931.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5338-45 [16707460.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):873-84 [16943400.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Nov;4(11):1358-65 [16996805.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1944-56 [17494927.001]
  • [Cites] J Clin Oncol. 2008 Feb 20;26(6):848-55 [18281656.001]
  • [Cites] J Natl Cancer Inst. 2008 Feb 20;100(4):261-9 [18270337.001]
  • [Cites] Circulation. 2008 Apr 22;117(16):2104-13 [18378608.001]
  • [Cites] Clin Cancer Res. 2009 Mar 15;15(6):2158-65 [19276291.001]
  • [Cites] Cell. 2009 Mar 20;136(6):1136-47 [19303855.001]
  • [Cites] Cancer Prev Res (Phila). 2009 Apr;2(4):322-9 [19336727.001]
  • (PMID = 19843689.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P01 ES013125; United States / NIDDK NIH HHS / DK / DK48831; United States / NCI NIH HHS / CA / T32 CA09685; United States / NCRR NIH HHS / RR / UL1 RR024996; United States / NCI NIH HHS / CA / P01 CA106451; United States / NIEHS NIH HHS / ES / ES013125-01A10002; United States / NIGMS NIH HHS / GM / GM15431; United States / NIGMS NIH HHS / GM / P50 GM015431-40; United States / NIDDK NIH HHS / DK / R01 DK048831; United States / NCI NIH HHS / CA / P01 CA77839; United States / NCI NIH HHS / CA / P01 CA077839; United States / NCI NIH HHS / CA / CA106451-05; United States / NCI NIH HHS / CA / T32 CA009685; United States / NCI NIH HHS / CA / T32 CA009685-18; None / None / / T32 CA009685-18; United States / NIGMS NIH HHS / GM / P01 GM015431; United States / NIGMS NIH HHS / GM / P50 GM015431; United States / NIDDK NIH HHS / DK / R01 DK048831-13; United States / NIEHS NIH HHS / ES / P01 ES013125-01A10002; United States / NIGMS NIH HHS / GM / GM015431-40; United States / NCI NIH HHS / CA / CA077839-100006; United States / NIEHS NIH HHS / ES / ES13125; United States / NCRR NIH HHS / RR / UL1-RR024996; United States / NCRR NIH HHS / RR / UL1 RR024996-03; United States / NCI NIH HHS / CA / P01 CA106451-05; None / None / / UL1 RR024996-03; United States / NIDDK NIH HHS / DK / DK048831-13; United States / NCI NIH HHS / CA / P01 CA077839-100006
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclooxygenase 2 Inhibitors; 0 / Prostaglandins; 73303-30-7 / 7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  • [Other-IDs] NLM/ NIHMS146126; NLM/ PMC2784194
  •  go-up   go-down


15. Otto SD, Lee L, Buhr HJ, Frericks B, Höcht S, Kroesen AJ: Staging anal cancer: prospective comparison of transanal endoscopic ultrasound and magnetic resonance imaging. J Gastrointest Surg; 2009 Jul;13(7):1292-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Staging anal cancer: prospective comparison of transanal endoscopic ultrasound and magnetic resonance imaging.
  • PURPOSE: The staging of anal cancer is extremely important for therapy and prognosis.
  • METHODS: Forty-five anal cancer patients underwent endoscopic ultrasound and magnetic resonance imaging.
  • For six patients who were operated upon because of tumor progression, the results were evaluated against the histological tumor stage.
  • Cancer patients were correctly identified with 100% sensitivity (45/45) by endoscopic ultrasound and with 88.9% (40/45) sensitivity by magnetic resonance imaging.
  • In the six operated patients, T stage was correctly assessed in four of six patients by endoscopic ultrasound and in three of six patients by magnetic resonance imaging.
  • [MeSH-major] Anus Neoplasms / diagnostic imaging. Anus Neoplasms / pathology. Endosonography. Magnetic Resonance Imaging. Neoplasm Staging / methods
  • [MeSH-minor] Adenocarcinoma / diagnostic imaging. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Biopsy, Needle. Carcinoma, Squamous Cell / diagnostic imaging. Carcinoma, Squamous Cell / pathology. Cohort Studies. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness / diagnostic imaging. Neoplasm Invasiveness / pathology. Prospective Studies. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2008 Jun 14;14 (22):3504-10 [18567078.001]
  • [Cites] Surg Endosc. 2008 Nov;22(11):2412-5 [18622554.001]
  • [Cites] Int J Colorectal Dis. 2000 Nov;15(5-6):282-90 [11151431.001]
  • [Cites] Endoscopy. 1995 Sep;27(7):469-79 [8565885.001]
  • [Cites] Surg Endosc. 2000 Nov;14 (11):1005-9 [11116406.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] World J Gastroenterol. 2007 Feb 14;13(6):895-900 [17352019.001]
  • [Cites] Dis Colon Rectum. 2002 Jan;45(1):16-22 [11786758.001]
  • [Cites] Dis Colon Rectum. 1986 Apr;29(4):234-42 [3512199.001]
  • [Cites] Int J Colorectal Dis. 1991 Aug;6(3):152-7 [1744487.001]
  • [Cites] Clin Radiol. 2005 Oct;60(10):1111-9 [16179172.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Int J Colorectal Dis. 1992 Sep;7(3):122-4 [1402307.001]
  • [Cites] Int J Colorectal Dis. 2007 Oct;22(10 ):1261-8 [17294198.001]
  • [Cites] Int J Colorectal Dis. 1991 Feb;6(1):2-4 [2033348.001]
  • [Cites] Dis Colon Rectum. 1978 Mar;21(2):89-91 [648293.001]
  • [Cites] Cancer Invest. 2006 Aug-Sep;24(5):535-44 [16939964.001]
  • [Cites] AJR Am J Roentgenol. 2006 Jan;186(1):144-8 [16357394.001]
  • [Cites] Radiology. 2004 Sep;232(3):773-83 [15273331.001]
  • [Cites] Eur J Radiol. 2007 Mar;61(3):480-9 [17188828.001]
  • [Cites] N Engl J Med. 2003 Jun 19;348(25):2491-9 [12815134.001]
  • [Cites] Int J Colorectal Dis. 2007 Nov;22(11):1347-52 [17643251.001]
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):792-800 [10717015.001]
  • [Cites] Endoscopy. 2001 Mar;33(3):231-6 [11293755.001]
  • [Cites] Int J Colorectal Dis. 2007 Feb;22(2):191-9 [16799791.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1686-93 [10223561.001]
  • [Cites] Int J Colorectal Dis. 1992 Dec;7(4):192-6 [1293239.001]
  • [Cites] Dis Colon Rectum. 1974 Mar-Apr;17(2):181-7 [4819268.001]
  • [Cites] Radiol Med. 2003 Oct;106(4):329-37 [14612825.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):794-800 [17379452.001]
  • [Cites] Dis Colon Rectum. 1981 Mar-Apr;24(2):73-5 [7215078.001]
  • [Cites] Radiology. 2007 Jan;242(1):137-43 [17090719.001]
  • [Cites] J Ultrasound Med. 2006 Jan;25(1):57-73 [16371556.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Radiology. 1990 May;175(2):494-8 [2326475.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):92-102 [15629599.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • (PMID = 19365694.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Denoya P, Wang H, Sands D, Nogueras J, Weiss E, Wexner SD: Short-term outcomes of laparoscopic total mesorectal excision following neoadjuvant chemoradiotherapy. Surg Endosc; 2010 Apr;24(4):933-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The laparoscopic approach for colon cancer has been widely accepted.
  • A few studies have shown that there are advantages of laparoscopic over open TME surgery for rectal cancer.
  • METHODS: All patients with rectal cancer who underwent nCRT were identified; no operations for rectal carcinoma were performed laparoscopically between 1997 and 2005.
  • The procedures performed within each group included 8 abdominoperineal resections and 24 anterior resections, which included 20 colonic J-pouch-anal anastomoses and 4 straight coloanal anastomoses.
  • There were no differences in comorbidities, tumor location, tumor size, tumor stage or radiation dose between the two groups.
  • CONCLUSIONS: In our experience, laparoscopic TME for mid and lower rectal cancer is feasible and safe.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surg Endosc. 2011 Jan;25(1):328-30 [20552370.001]
  • [Cites] Lancet Oncol. 2005 Jul;6(7):477-84 [15992696.001]
  • [Cites] Ann Surg. 2007 Oct;246(4):655-62; discussion 662-4 [17893502.001]
  • [Cites] Ann Surg Oncol. 2007 Apr;14(4):1285-7 [17235719.001]
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Br J Hosp Med. 1979 Sep;22(3):277-81 [391315.001]
  • [Cites] Dis Colon Rectum. 2007 Apr;50(4):464-71 [17195085.001]
  • [Cites] Br J Surg. 1982 Oct;69(10):613-6 [6751457.001]
  • [Cites] Colorectal Dis. 2006 Jun;8(5):375-88 [16684081.001]
  • [Cites] Dig Dis. 2007;25(1):94-9 [17384514.001]
  • [Cites] Br J Surg. 1980 Mar;67(3):198-200 [7362961.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1718-26 [15894098.001]
  • [Cites] Dis Colon Rectum. 1980 Apr;23 (3):202-5 [6991231.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):817-25 [11821466.001]
  • [Cites] Dig Surg. 2007;24(5):367-74 [17785982.001]
  • [Cites] Colorectal Dis. 2006 Jun;8(5):441-50 [16684090.001]
  • [Cites] Dis Colon Rectum. 1981 Sep;24(6):437-44 [7273981.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] J Gastrointest Surg. 2009 Mar;13(3):521-5 [19011946.001]
  • [Cites] Dis Colon Rectum. 1982 Sep;25(6):545-57 [6749455.001]
  • [Cites] Int J Colorectal Dis. 2007 Apr;22(4):367-72 [16786316.001]
  • [Cites] Dis Colon Rectum. 2001 Mar;44(3):315-21 [11289275.001]
  • [Cites] Am J Surg. 2008 Feb;195(2):233-8 [18083137.001]
  • [Cites] Dis Colon Rectum. 2007 Dec;50(12):2047-53 [17906896.001]
  • [Cites] J Clin Oncol. 2007 Nov 1;25(31):5040; author reply 5040-1 [17971609.001]
  • (PMID = 19851807.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


17. Yu J, Ohuchida K, Nakata K, Mizumoto K, Cui L, Fujita H, Yamaguchi H, Egami T, Kitada H, Tanaka M: LIM only 4 is overexpressed in late stage pancreas cancer. Mol Cancer; 2008;7:93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] LIM only 4 is overexpressed in late stage pancreas cancer.
  • BACKGROUND: LIM-only 4 (LMO4), a member of the LIM-only (LMO) subfamily of LIM domain-containing transcription factors, was initially reported to have an oncogenic role in breast cancer.
  • If so, this could result in a better understanding of tumorigenesis in pancreatic cancer.
  • METHODS: We measured LMO4 mRNA levels in cultured cells, pancreatic bulk tissues and microdissected target cells (normal ductal cells; pancreatic intraepithelial neoplasia-1B [PanIN-1B] cells; PanIN-2 cells; invasive ductal carcinoma [IDC] cells; intraductal papillary-mucinous adenoma [IPMA] cells; IPM borderline [IPMB] cells; and invasive and non-invasive IPM carcinoma [IPMC]) by quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR).
  • RESULTS: 9 of 14 pancreatic cancer cell lines expressed higher levels of LMO4 mRNA than did the human pancreatic ductal epithelial cell line (HPDE).
  • In bulk tissue samples, expression of LMO4 was higher in pancreatic carcinoma than in intraductal papillary-mucinous neoplasm (IPMN) or non-neoplastic pancreas (p < 0.0001 for both).
  • These results suggested that LMO4 is overexpressed at late stages in carcinogenesis of pancreatic cancer.
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Analysis of Variance. Carcinoma, Pancreatic Ductal / genetics. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / genetics. Carcinoma, Papillary / pathology. Cell Line, Tumor. Humans. LIM Domain Proteins. Neoplasm Staging. Protein-Serine-Threonine Kinases / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2003 May 19;88(10):1543-8 [12771919.001]
  • [Cites] Jpn J Clin Oncol. 2003 Feb;33(2):93-7 [12629061.001]
  • [Cites] Pancreas. 2004 Apr;28(3):219-30 [15084961.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3215-22 [15126362.001]
  • [Cites] Med Electron Microsc. 2004 Jun;37(2):82-8 [15221649.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 May 15;88(10):4367-71 [2034676.001]
  • [Cites] Oncogene. 1991 Oct;6(10):1887-93 [1923511.001]
  • [Cites] N Engl J Med. 1992 Feb 13;326(7):455-65 [1732772.001]
  • [Cites] EMBO J. 1994 Jul 15;13(14):3329-38 [8045262.001]
  • [Cites] Am J Pathol. 1994 Dec;145(6):1547-50 [7992857.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Jan;12(1):24-31 [7534107.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2527-30 [8653691.001]
  • [Cites] Nat Genet. 1998 Jan;18(1):38-43 [9425897.001]
  • [Cites] Pancreas. 1998 Apr;16(3):238-42 [9548661.001]
  • [Cites] Am J Pathol. 1998 Jul;153(1):263-9 [9665487.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 15;95(19):11257-62 [9736723.001]
  • [Cites] Biochim Biophys Acta. 1999 Apr 14;1445(1):148-53 [10209267.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1835-40 [10362809.001]
  • [Cites] Gene. 2005 Jan 3;344:67-77 [15656974.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7659-64 [15897450.001]
  • [Cites] Pancreas. 2005 Nov;31(4):344-9 [16258368.001]
  • [Cites] Rocz Akad Med Bialymst. 2005;50:69-72 [16358942.001]
  • [Cites] Biochem Biophys Res Commun. 2006 May 19;343(4):1186-90 [16580634.001]
  • [Cites] Oncogene. 2006 May 11;25(20):2920-30 [16331278.001]
  • [Cites] World J Gastroenterol. 2006 Jun 28;12(24):3878-82 [16804974.001]
  • [Cites] Oncogene. 2007 Sep 27;26(44):6431-41 [17452977.001]
  • [Cites] Br J Cancer. 2008 Feb 12;98(3):537-41 [18231110.001]
  • [Cites] Am J Pathol. 2000 Nov;157(5):1623-31 [11073822.001]
  • [Cites] Mamm Genome. 1999 Nov;10(11):1089-94 [10556429.001]
  • [Cites] Pancreatology. 2008;8(6):587-92 [18849640.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2017-22 [11733352.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14452-7 [11734645.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):62-77 [11815961.001]
  • [Cites] J Biol Chem. 2002 Mar 8;277(10):7849-56 [11751867.001]
  • [Cites] Int J Oncol. 2002 Nov;21(5):1067-72 [12370756.001]
  • [Cites] Carcinogenesis. 2003 Feb;24(2):193-8 [12584167.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2003;10(2):125-36 [14505145.001]
  • (PMID = 19099607.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Homeodomain Proteins; 0 / LIM Domain Proteins; 0 / LMO4 protein, human; 0 / RNA, Messenger; 0 / Transcription Factors; EC 2.7.1.- / STK11 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Other-IDs] NLM/ PMC2628350
  •  go-up   go-down


18. Yamashita S, Masui T, Katayama M, Sato K, Yoshizawa N, Seo H, Sakahara H: T2-weighted MRI of rectosigmoid carcinoma: comparison of respiratory-triggered fast spin-echo, breathhold fast-recovery fast spin-echo, and breathhold single-shot fast spin-echo sequences. J Magn Reson Imaging; 2007 Mar;25(3):511-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T2-weighted MRI of rectosigmoid carcinoma: comparison of respiratory-triggered fast spin-echo, breathhold fast-recovery fast spin-echo, and breathhold single-shot fast spin-echo sequences.
  • MATERIALS AND METHODS: Forty patients (stage: pT0, 1; pTis-2, 15; pT3-4, 24) were included in the study.
  • All examinations were performed on a 1.5T magnet with a phased-array coil and the patients were studied in the prone position with per-anal air injection.
  • CONCLUSION: The BH-FRFSE sequence may be the first choice for rectosigmoid T2W imaging in the prone position with per-anal air injection for patients who can hold their breath stably.
  • [MeSH-major] Carcinoma / diagnosis. Magnetic Resonance Imaging / methods. Rectal Neoplasms / diagnosis. Respiration. Sigmoid Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Artifacts. Diagnosis, Differential. Echo-Planar Imaging / methods. Female. Humans. Male. Middle Aged. Observer Variation. Prospective Studies. ROC Curve

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17326094.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Zhu X, Ma LL, Ye T: Expression of CD4(+)CD25(high)CD127(low/-) regulatory T cells in transitional cell carcinoma patients and its significance. J Clin Lab Anal; 2009;23(4):197-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of CD4(+)CD25(high)CD127(low/-) regulatory T cells in transitional cell carcinoma patients and its significance.
  • To evaluate the expressions of CD4(+)CD25(high)CD127(low/-) regulatory T cells (Tregs) in peripheral blood from patients with transitional cell carcinoma (TCC) in urinary system, we investigated the proportion of Treg population in CD4(+) T from 93 patients with TCC, 38 with benign urinary diseases, and 37 healthy subjects by using flow cytometric analysis and analyzing different clinicopathologic characteristics and the changes before and after operation.
  • There was a strong correlation between the proportion of Treg and tumor recurrence, quantity, lymph node metastasis (P<0.01), as well as pathological stage; no correlation was found between the proportion of Treg and clinical TNM stage (P>0.05).
  • [MeSH-major] Antigens, CD / immunology. Biomarkers, Tumor / blood. Carcinoma, Transitional Cell / immunology. T-Lymphocytes, Regulatory / immunology. Urologic Neoplasms / immunology

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19623656.001).
  • [ISSN] 1098-2825
  • [Journal-full-title] Journal of clinical laboratory analysis
  • [ISO-abbreviation] J. Clin. Lab. Anal.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD4; 0 / Biomarkers, Tumor; 0 / IL2RA protein, human; 0 / Interleukin-2 Receptor alpha Subunit; 0 / Interleukin-7 Receptor alpha Subunit
  •  go-up   go-down


20. Krengli M, Milia ME, Turri L, Mones E, Bassi MC, Cannillo B, Deantonio L, Sacchetti G, Brambilla M, Inglese E: FDG-PET/CT imaging for staging and target volume delineation in conformal radiotherapy of anal carcinoma. Radiat Oncol; 2010;5:10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET/CT imaging for staging and target volume delineation in conformal radiotherapy of anal carcinoma.
  • BACKGROUND: FDG-PET/CT imaging has an emerging role in staging and treatment planning of various tumor locations and a number of literature studies show that also the carcinoma of the anal canal may benefit from this diagnostic approach.
  • We analyzed the potential impact of FDG-PET/CT in stage definition and target volume delineation of patients affected by carcinoma of the anal canal and candidates for curative radiotherapy.
  • METHODS: Twenty seven patients with biopsy proven anal carcinoma were enrolled.
  • Pathology was squamous cell carcinoma in 20 cases, cloacogenic carcinoma in 3, adenocarcinoma in 2, and basal cell carcinoma in 2.
  • RESULTS: PET/CT fused images led to change the stage in 5/27 cases (18.5%): 3 cases from N0 to N2 and 2 from M0 to M1 leading to change the treatment intent from curative to palliative in a case.Based on PET/CT imaging, GTV and CTV contours changed in 15/27 (55.6%) and in 10/27 cases (37.0%) respectively.
  • CONCLUSIONS: FDG-PET/CT has a potential relevant impact in staging and target volume delineation of the carcinoma of the anal canal.
  • Clinical stage variation occurred in 18.5% of cases with change of treatment intent in 3.7%.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma / pathology. Neoplasm Staging / methods. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Conformal

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 2001 Oct;61(1):15-22 [11578724.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):824-30 [19117696.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):893-900 [15936575.001]
  • [Cites] Mol Imaging Biol. 2005 Jul-Aug;7(4):309-13 [16028002.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):720-5 [16626889.001]
  • [Cites] Technol Cancer Res Treat. 2007 Feb;6(1):31-6 [17241098.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):155-62 [17707268.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1423-6 [17931795.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):180-6 [17996387.001]
  • [Cites] Med Phys. 2008 Apr;35(4):1207-13 [18491512.001]
  • [Cites] Radiother Oncol. 2008 Jun;87(3):376-82 [18453023.001]
  • [Cites] Br J Cancer. 2009 Mar 10;100(5):693-700 [19259091.001]
  • [Cites] Strahlenther Onkol. 2009 Apr;185(4):254-9 [19370429.001]
  • [Cites] Br J Radiol. 2009 Jun;82(978):509-13 [19153180.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • (PMID = 20137093.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ PMC2851594
  •  go-up   go-down


21. Looi ML, Dali AZ, Ali SA, Ngah WZ, Yusof YA: Expression of p53, bcl-2 and Ki-67 in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the uterine cervix. Anal Quant Cytol Histol; 2008 Apr;30(2):63-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p53, bcl-2 and Ki-67 in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the uterine cervix.
  • STUDY DESIGN: A total of 131 cervical specimens, consisting of normal cervical epithelium (n = 43), cervical intraepithelial neoplasia (CIN) lesions (n =40) and cervical squamous cell carcinomas (SCCs) (n = 48) were examined immunohistochemically in paraffin sections for expression of p53, bcl-2 and Ki-67.
  • CONCLUSION: HGCIN is an early stage to demonstrate the alteration of bcl-2 and Ki-67 expressions.


22. Li CS, Wan DS, Pan ZZ, Zhou ZW, Chen G, Wu XJ, Li LR, Lu ZH, Ding PR, Li Y: [Multivariate prognostic analysis of patients with low and middle rectal cancer after curative resection]. Ai Zheng; 2006 May;25(5):587-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multivariate prognostic analysis of patients with low and middle rectal cancer after curative resection].
  • BACKGROUND & OBJECTIVE: The incidence of low and middle rectal cancer is high in China.
  • This study was to evaluate the correlation of clinicopathologic features to the prognosis in low and middle rectal cancer.
  • METHODS: The clinicopathologic data of 599 patients with low and middle rectal cancer, treated from 1990 to 1999 in Cancer Center of Sun Yat-sen University, were analyzed retrospectively.
  • Univariate analysis showed that local recurrence, perioperative blood transfusion, lymph node metastasis, T stage, histology, macropathology, operation pattern, and distance from anal margin were correlated to prognosis (P<0.05).
  • Multivariate analysis showed that local recurrence, perioperative blood transfusion, lymph node metastasis, and T stage were independent prognostic factors (P<0.01).
  • CONCLUSIONS: Local recurrence, perioperative blood transfusion, lymph node metastasis, and T stage are important prognostic factors of low and middle rectal cancer.
  • LAR has become the preferred option in curative surgery for low and middle rectal cancer.
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Blood Transfusion. Carcinoma, Signet Ring Cell / pathology. Carcinoma, Signet Ring Cell / surgery. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Proportional Hazards Models. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Rectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16687079.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


23. Attia S, Traynor AM, Kim K, Merchant JJ, Hoang T, Ahuja HG, Beatty PA, Hansen RM, Masters GA, Oettel KR, Shapiro GR, Larson MM, Larson ML, Schiller JH: Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study. J Thorac Oncol; 2008 Sep;3(9):1018-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study.
  • INTRODUCTION: Exisulind is an apoptotic agent with preclinical activity in non-small cell lung cancer (NSCLC).
  • METHODS: Chemotherapy-naive patients >/=70-years-old with stage IIIB-IV NSCLC and a performance status (PS) </=2 were eligible.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6178-84 [10626810.001]
  • [Cites] Oncologist. 2007 Dec;12(12):1416-24 [18165618.001]
  • [Cites] Cancer. 2000 Jun 15;88(12):2677-85 [10870049.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3338-42 [10910034.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2690-5 [10914711.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):4136-41 [11051267.001]
  • [Cites] Oncologist. 2001;6 Suppl 1:4-7 [11181997.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):494-502 [11786579.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):904-12 [11895925.001]
  • [Cites] Mol Cancer Ther. 2003 May;2(5):479-88 [12748310.001]
  • [Cites] Eur J Cancer. 2003 Nov;39(16):2264-72 [14556916.001]
  • [Cites] J Am Geriatr Soc. 1968 May;16(5):622-6 [5646906.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] Clin Pharmacol Ther. 1985 Aug;38(2):228-34 [4017423.001]
  • [Cites] Clin Pharmacol Ther. 1985 Oct;38(4):387-93 [4042521.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] J Pharm Biomed Anal. 1995 Dec;14(1-2):213-20 [8833984.001]
  • [Cites] Eur J Cancer. 1997 Feb;33(2):301-3 [9135505.001]
  • [Cites] Eur J Cancer. 1997 Mar;33(3):392-7 [9155522.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2452-9 [9192825.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1250-9 [9849488.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2831-9 [15837997.001]
  • [Cites] J Clin Oncol. 2005 May 1;23(13):3125-37 [15860872.001]
  • [Cites] Clin Lung Cancer. 2005 May;6(6):361-6 [15943897.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5892-9 [16043829.001]
  • [Cites] Cancer. 2005 Nov 1;104(9):1998-2005 [16206252.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3187-205 [16682719.001]
  • [Cites] Eur J Cancer. 2006 Oct;42(15):2433-53 [16750358.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Cancer Control. 2007 Jan;14(1):32-43 [17242669.001]
  • [Cites] J Thorac Oncol. 2006 Mar;1(3):218-25 [17409860.001]
  • [Cites] J Thorac Oncol. 2006 Sep;1(7):673-8 [17409935.001]
  • [Cites] J Clin Oncol. 2007 May 10;25(14):1824-31 [17488980.001]
  • [Cites] J Thorac Oncol. 2007 Oct;2(10):933-8 [17909356.001]
  • [Cites] J Clin Oncol. 2007 Dec 1;25(34):5381-9 [18048819.001]
  • [Cites] Clin Cancer Res. 2000 Jan;6(1):78-89 [10656435.001]
  • (PMID = 18758305.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA014520-33; United States / NCI NIH HHS / CA / T32 CA009614-18; United States / NCI NIH HHS / CA / CA062491-14; United States / NCI NIH HHS / CA / CA014520-34S2; United States / NCI NIH HHS / CA / T32 CA009614-14; United States / NCI NIH HHS / CA / T32 CA009614-11; United States / NCI NIH HHS / CA / T32 CA009614-10; United States / NCI NIH HHS / CA / CA009614-15; United States / NCI NIH HHS / CA / T32 CA009614-15; United States / NCI NIH HHS / CA / CA087718-08; United States / NCI NIH HHS / CA / CA009614-16A1; United States / NCI NIH HHS / CA / CA014520-31S1; United States / NCI NIH HHS / CA / P30 CA014520-33S1; United States / NCI NIH HHS / CA / P30 CA014520-32; None / None / / P30 CA014520-33; United States / NCI NIH HHS / CA / T32 CA009614-16A1; United States / NCI NIH HHS / CA / P30 CA014520-32S1; United States / NCI NIH HHS / CA / K12 CA087718-07; United States / NCI NIH HHS / CA / P30 CA014520-34; United States / NCI NIH HHS / CA / U01 CA062491-11; United States / NCI NIH HHS / CA / P30 CA014520; None / None / / P30 CA014520-32; United States / NCI NIH HHS / CA / CA014520-34S1; United States / NCI NIH HHS / CA / U01 CA062491-10; United States / NCI NIH HHS / CA / CA062491-11; United States / NCI NIH HHS / CA / CA062491-13; United States / NCI NIH HHS / CA / P30 CA014520-33S2; United States / NCI NIH HHS / CA / CA009614-14; United States / NCI NIH HHS / CA / P30 CA014520-31; United States / NCI NIH HHS / CA / U01 CA062491; United States / NCI NIH HHS / CA / K12 CA087718; United States / NCI NIH HHS / CA / CA009614-12; None / None / / P30 CA014520-30; United States / NCI NIH HHS / CA / CA014520-33S2; United States / NCI NIH HHS / CA / U01 CA062491-13; United States / NCI NIH HHS / CA / CA009614-17; United States / NCI NIH HHS / CA / P30 CA014520-31S1; United States / NCI NIH HHS / CA / CA014520-32S1; United States / NCI NIH HHS / CA / P30 CA14520; United States / NCI NIH HHS / CA / T32 CA009614; United States / NCI NIH HHS / CA / CA009614-11; None / None / / P30 CA014520-34; United States / NCI NIH HHS / CA / P30 CA014520-30; United States / NCI NIH HHS / CA / T32 CA009614-13; None / None / / P30 CA014520-31; United States / NCI NIH HHS / CA / CA009614-18; United States / NCI NIH HHS / CA / CA062491-12; United States / NCI NIH HHS / CA / P30 CA014520-34S1; United States / NCI NIH HHS / CA / CA009614-13; United States / NCI NIH HHS / CA / T32 CA009614-17; United States / NCI NIH HHS / CA / U01 CA062491-12; United States / NCI NIH HHS / CA / T32 CA009614-12; United States / NCI NIH HHS / CA / U01 CA062491-14; United States / NCI NIH HHS / CA / P30 CA014520-34S2; United States / NCI NIH HHS / CA / K12 CA087718-08; United States / NCI NIH HHS / CA / CA009614-10; United States / NCI NIH HHS / CA / CA014520-33S1
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 184SNS8VUH / Sulindac; 5V9KLZ54CY / Vinblastine; K619IIG2R9 / sulindac sulfone; Q6C979R91Y / vinorelbine
  • [Other-IDs] NLM/ NIHMS52764; NLM/ PMC2562273
  •  go-up   go-down


24. Abramowitz L, Mathieu N, Roudot-Thoraval F, Lemarchand N, Bauer P, Hennequin C, Mitry E, Romelaer C, Aparicio T, Sobhani I: Epidermoid anal cancer prognosis comparison among HIV+ and HIV- patients. Aliment Pharmacol Ther; 2009 Aug 15;30(4):414-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermoid anal cancer prognosis comparison among HIV+ and HIV- patients.
  • BACKGROUND: Previous studies suggest a poor prognosis of epidermoid anal cancer in HIV+ patients.
  • AIM: To investigate the long-term outcome of epidermoid anal cancer in HIV+ and HIV- patients in the highly active antiretroviral treatment (HAART) era.
  • METHODS: We included all patients with epidermoid anal cancer referred to six hospitals from 1998 to 2004.
  • No significant differences were observed in the tumour stage, pelvic radiotherapy dose or concomitant chemotherapy, according to the HIV status.
  • CONCLUSIONS: The clinical outcome of HIV+ patients with epidermoid anal cancer is similar to that of HIV- patients.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. HIV Infections / drug therapy. HIV Seropositivity / complications


25. Han JG, Wei GH, Gao ZG, Zheng Y, Wang ZJ: Intersphincteric resection with direct coloanal anastomosis for ultralow rectal cancer: the experience of People's Republic of China. Dis Colon Rectum; 2009 May;52(5):950-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intersphincteric resection with direct coloanal anastomosis for ultralow rectal cancer: the experience of People's Republic of China.
  • PURPOSE: The purpose of this study was to evaluate the oncologic and functional outcomes of intersphincteric resection in ultralow rectal cancer.
  • METHODS: From 2000 to 2007, intersphincteric resection with total mesorectal excision was performed in 40 patients with very low rectal cancer (total intersphincteric resection in 5 patients, partial intersphincteric resection in 23 patients, and partial intersphincteric resection with partial dentate line preservation [modified partial intersphincteric resection] in 12 patients).
  • The preoperative tumor stage was T12N01M0.
  • A temporary diverting stoma may be beneficial to improve anal function.
  • Modified partial intersphincteric resection under the precondition of radical resection yielded better anal function and a lower rate of incontinence.
  • [MeSH-major] Anal Canal / surgery. Anastomosis, Surgical / methods. Colon / surgery. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Carcinoma / mortality. Carcinoma / pathology. Carcinoma / surgery. Defecation. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Surgical Stomas. Survival Rate

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19502861.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


26. Stewart D, Yan Y, Kodner IJ, Birnbaum E, Fleshman J, Myerson R, Dietz D: Salvage surgery after failed chemoradiation for anal canal cancer: should the paradigm be changed for high-risk tumors? J Gastrointest Surg; 2007 Dec;11(12):1744-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage surgery after failed chemoradiation for anal canal cancer: should the paradigm be changed for high-risk tumors?
  • It is common belief that patients failing chemoradiation therapy (CRT) for squamous cell cancer of the anus (SCCA) can be salvaged with subsequent surgery.
  • Initial tumors were AJCC stage 2 (16 cases), 3A (3 cases), and 4 (1 case).
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Salvage Therapy


27. Myerson RJ, Outlaw ED, Chang A, Birnbaum EH, Fleshman JW, Grigsby PW, Kodner IJ, Malayapa RS, Mutch MG, Parikh P, Picus J, Tan BR: Radiotherapy for epidermoid carcinoma of the anus: thirty years' experience. Int J Radiat Oncol Biol Phys; 2009 Oct 1;75(2):428-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy for epidermoid carcinoma of the anus: thirty years' experience.
  • PURPOSE: To evaluate the factors associated with disease control and morbidity after radiotherapy for anal carcinoma.
  • METHODS AND MATERIALS: Between 1975 and 2005, 194 patients with localized epidermoid anal carcinoma underwent radiotherapy.
  • Univariate analysis for UNED survival showed a strong association with the T and N stage (5-year UNED rate, 88.5% +/- 3.4% for those with Stage T1-T2N0; 70.1% +/- 4.2% for Stage T3N0; and 52.7% +/- 6.6% for Stage III; p > .001) and mobility on palpation (5-year UNED rate, 89.2% +/- 4.6% for those with mobile tumors vs. 59.3% +/- 6.1% for those with tethered/fixed tumor; p > .001).
  • Of the 194 patients, 56 had 68 additional malignancies, mainly either antedating the anal cancer or outside the radiation fields.
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy


28. Kayes OJ, Loddo M, Patel N, Patel P, Minhas S, Ambler G, Freeman A, Wollenschlaeger A, Ralph DJ, Stoeber K, Williams GH: DNA replication licensing factors and aneuploidy are linked to tumor cell cycle state and clinical outcome in penile carcinoma. Clin Cancer Res; 2009 Dec 01;15(23):7335-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA replication licensing factors and aneuploidy are linked to tumor cell cycle state and clinical outcome in penile carcinoma.
  • We have analyzed replication licensing factors (RLF), together with DNA ploidy status, to investigate their role in progression of penile squamous cell carcinoma and to assess their utility as novel prognostic tools.
  • Accelerated cell cycle progression was linked to increasing tumor size, stage, and depth of invasion.
  • Our results also identify the DNA replication initiation pathway as a potentially attractive therapeutic target in penile squamous cell carcinoma.
  • [MeSH-major] Aneuploidy. Carcinoma / genetics. Carcinoma / therapy. Gene Expression Regulation, Neoplastic. Penile Neoplasms / genetics. Penile Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Cycle. Cell Cycle Proteins / biosynthesis. Cohort Studies. Geminin. Gene Expression Profiling. Humans. Ki-67 Antigen / biosynthesis. Male. Middle Aged. Minichromosome Maintenance Complex Component 2. Nuclear Proteins / biosynthesis. Ploidies. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2009 Mar 24;100(6):959-70 [19240714.001]
  • [Cites] Br J Cancer. 2005 Nov 28;93(11):1295-300 [16278669.001]
  • [Cites] IARC Sci Publ. 1992;(120):45-173 [1284606.001]
  • [Cites] J Urol. 1993 Mar;149(3):492-7 [8437253.001]
  • [Cites] Nat Chem Biol. 2008 Jun;4(6):331-2 [18488006.001]
  • [Cites] Br J Cancer. 2009 Apr 7;100(7):1128-34 [19293805.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2121-32 [10473096.001]
  • [Cites] J Natl Cancer Inst. 2002 Jul 17;94(14):1071-9 [12122098.001]
  • [Cites] J Urol. 2006 May;175(5):1700-4; discussion 1704-5 [16600735.001]
  • [Cites] Acta Neuropathol. 2007 Feb;113(2):119-27 [17160531.001]
  • [Cites] BJU Int. 2006 Sep;98(3):526-31 [16925747.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2712-8 [11555583.001]
  • [Cites] Br J Urol. 1993 Dec;72(6):941-5 [8306161.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):845-56 [16239904.001]
  • [Cites] Am J Surg Pathol. 1998 Jun;22(6):755-61 [9630184.001]
  • [Cites] Clin Cancer Res. 2009 Apr 1;15(7):2417-25 [19318489.001]
  • [Cites] Nat Rev Cancer. 2006 Sep;6(9):735-41 [16915294.001]
  • [Cites] Eur Urol. 2004 Jul;46(1):1-8 [15183542.001]
  • [Cites] Br J Cancer. 2004 Jul 19;91(2):262-9 [15199392.001]
  • [Cites] Urol Clin North Am. 1992 May;19(2):247-56 [1574815.001]
  • [Cites] Exp Cell Res. 2005 Sep 10;309(1):56-67 [16005865.001]
  • [Cites] EMBO J. 1998 Dec 15;17(24):7219-29 [9857179.001]
  • [Cites] J Pathol. 2005 Feb;205(3):318-28 [15682442.001]
  • [Cites] J Cell Sci. 2004 Nov 15;117(Pt 24):5875-86 [15522891.001]
  • [Cites] Trends Cell Biol. 2002 Feb;12(2):72-8 [11849970.001]
  • [Cites] J Urol. 2005 Mar;173(3):816-9 [15711276.001]
  • [Cites] Clin Cancer Res. 2007 Oct 15;13(20):6153-61 [17947481.001]
  • [Cites] Curr Opin Cell Biol. 2007 Dec;19(6):672-9 [18032010.001]
  • [Cites] J Urol. 2006 Jun;175(6):2103-8; discussion 2108 [16697813.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14932-7 [9843993.001]
  • [Cites] Exp Cell Res. 2007 Oct 15;313(17):3789-99 [17689530.001]
  • [Cites] Br J Urol. 1993 Nov;72(5 Pt 2):817-9 [8281416.001]
  • [Cites] Anal Cell Pathol. 1998;17(4):189-200 [10391371.001]
  • [Cites] Br J Cancer. 2004 Aug 16;91(4):714-9 [15266314.001]
  • [Cites] Nat Rev Cancer. 2008 Oct;8(10):799-806 [18756287.001]
  • [Cites] Gut. 2002 Mar;50(3):373-7 [11839717.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Jun;6(6):476-86 [15928711.001]
  • [Cites] Annu Rev Biochem. 2002;71:333-74 [12045100.001]
  • [Cites] J Surg Oncol. 2008 May 1;97(6):487-95 [18425779.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):267-73 [12107111.001]
  • [Cites] Br J Cancer. 2007 May 7;96(9):1384-93 [17406359.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4306-13 [14645419.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2510-7 [15814627.001]
  • [Cites] Nat Rev Cancer. 2003 Mar;3(3):217-26 [12612656.001]
  • [Cites] Lancet. 1999 Oct 30;354(9189):1524-5 [10551502.001]
  • [Cites] Br J Cancer. 2003 Sep 15;89(6):1048-54 [12966424.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2855-64 [18843031.001]
  • [Cites] Anal Quant Cytol Histol. 2007 Aug;29(4):185-98 [17879626.001]
  • [Cites] Ann Surg. 1921 Feb;73(2):141-60 [17864409.001]
  • [Cites] Br J Cancer. 2008 May 6;98(9):1548-54 [18414413.001]
  • [Cites] J Cell Sci. 2001 Jun;114(Pt 11):2027-41 [11493639.001]
  • (PMID = 19920109.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / A6263
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / GMNN protein, human; 0 / Geminin; 0 / Ki-67 Antigen; 0 / Nuclear Proteins; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  • [Other-IDs] NLM/ PMC2788529; NLM/ UKMS27727
  •  go-up   go-down


29. Pasetto LM, Friso ML, Pucciarelli S, Basso U, Toppan P, Rugge M, Sinigaglia G, Nitti D, Sotti G, Monfardini S: Primary rectal carcinoma in patients with stage IV resectable disease at diagnosis. Anticancer Res; 2007 Mar-Apr;27(2):1079-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary rectal carcinoma in patients with stage IV resectable disease at diagnosis.
  • BACKGROUND: Rectal cancer is commonly diagnosed at a precocious stage, but for patients presenting at diagnosis with stage IV disease the best treatment is still undefined.
  • The purpose of this study was to review the feasibility and outcome of multimodality treatment of rectal cancer patients metastatic at diagnosis.
  • PATIENTS AND METHODS: From January 2000 to December 2005, 40 patients with histologically proven stage IV rectal adenocarcinoma (< 12 cm from the anal verge) were examined.
  • CONCLUSION: The best treatment on diagnosis of metastatic rectal cancer is a multimodality CHT-RT approach.

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17465247.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


30. Chen R, Pan S, Duan X, Nelson BH, Sahota RA, de Rham S, Kozarek RA, McIntosh M, Brentnall TA: Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia. Mol Cancer; 2010 Jun 15;9:149
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Pancreatic intraepithelial neoplasias (PanINs) are precursors of malignant pancreatic cancer, an ideal stage for early cancer detection.
  • An ELISA assay was developed to evaluate AGR2 levels in 51 pancreatic juice samples and 23 serum samples from patients with pancreatic cancer, pre-malignant lesions (including PanIN3, PanIN2, Intraductal Papillary Mucinous Neoplasms (IPMNs)) and benign disease controls (including chronic pancreatitis).
  • AGR2 levels in the pancreatic juice samples were found significantly elevated in patients with pre-malignant conditions (PanINs and IPMNs) as well as pancreatic cancer compared to control samples (p < or = 0.03).
  • CONCLUSIONS: These results suggest that elevation of AGR2 levels in pancreatic juice occurs in early pancreatic cancer progression and could be further investigated as a potential candidate juice biomarker for early detection of pancreatic cancer.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47 [11814064.001]
  • [Cites] Clin Sci (Lond). 2010 Jun;118(12):717-25 [20136634.001]
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • [Cites] Anal Chem. 2003 Sep 1;75(17):4646-58 [14632076.001]
  • [Cites] Pancreas. 1994 Nov;9(6):741-7 [7846018.001]
  • [Cites] Mech Dev. 1998 Mar;72(1-2):115-30 [9533957.001]
  • [Cites] Ann Intern Med. 1999 Aug 17;131(4):247-55 [10454945.001]
  • [Cites] Mol Cell Proteomics. 2004 Dec;3(12):1154-69 [15385600.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):523-33 [15684406.001]
  • [Cites] Oncogene. 2005 Oct 6;24(44):6626-36 [16103885.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):405-11 [16052519.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1208-17 [16424060.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1728-34 [16551856.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2066-9 [16609017.001]
  • [Cites] Histol Histopathol. 2007 Jul;22(7):703-8 [17455144.001]
  • [Cites] Semin Oncol. 2007 Aug;34(4):303-10 [17674958.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2007;10(3):293-300 [17457305.001]
  • [Cites] Curr Opin Gastroenterol. 2007 Sep;23(5):508-14 [17762556.001]
  • [Cites] J Natl Compr Canc Netw. 2007 Nov;5(10):1034-41 [18053427.001]
  • [Cites] Cancer Res. 2008 Jan 15;68(2):492-7 [18199544.001]
  • [Cites] EMBO Rep. 2008 May;9(5):429-34 [18451766.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7811-8 [18829536.001]
  • [Cites] Cancer Detect Prev. 2008;32(3):236-50 [18801625.001]
  • [Cites] Cancer Biol Ther. 2009 Feb;8(4):340-6 [19106647.001]
  • [Cites] PLoS Med. 2009 Apr 7;6(4):e1000046 [19360088.001]
  • [Cites] Electrophoresis. 2009 Apr;30(7):1132-44 [19373808.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):6950-5 [19359471.001]
  • [Cites] Histol Histopathol. 2009 Sep;24(9):1121-8 [19609859.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1868-75 [11912167.001]
  • (PMID = 20550709.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01DK081368; United States / NCI NIH HHS / CA / CA116296-02; United States / NCI NIH HHS / CA / K07 CA116296-02; United States / NCI NIH HHS / CA / K07 CA116296; United States / NCI NIH HHS / CA / R01CA107209; United States / NCI NIH HHS / CA / K07CA116296; United States / NCI NIH HHS / CA / K25CA137222
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proteins; EC 5.3.4.1 / AGR2 protein, human
  • [Other-IDs] NLM/ PMC2893103
  •  go-up   go-down


31. Seo Y, Kinsella MT, Reynolds HL, Chipman G, Remick SC, Kinsella TJ: Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients. Int J Radiat Oncol Biol Phys; 2009 Sep 1;75(1):143-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients.
  • PURPOSE: Information is limited as to how we should treat invasive anal squamous cell carcinoma (SCC) in patients with chronic immunosuppression, since the majority of clinical studies to date have excluded such patients.
  • The objective of this study is to compare treatment outcomes in immunocompetent (IC) versus immunodeficient (ID) patients with invasive anal SCC treated similarly with combined modality therapy.
  • There were no significant differences in tumor size, T stage, N stage, chemotherapy doses, or radiation doses between the two groups.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Radiotherapy, Conformal

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19203845.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


32. Weroha SJ, Lingle WL, Hong Y, Li SA, Li JJ: Specific overexpression of cyclin E·CDK2 in early preinvasive and primary breast tumors in female ACI rats induced by estrogen. Horm Cancer; 2010 Feb;1(1):34-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cyclin E1·CDK2 overexpression plays an important dual role in late G1/S phase of the cell cycle in cancer cells.
  • It increases DNA replication providing growth advantage to cancer cells and facilitates aberrant centrosome duplication, generating chromosomal instability and aneuploidy leading to tumor development.
  • Cyclin E·CDK2 positive staining was confined to the large round cells found within focal dysplasias, ductal carcinomas in situ, and invasive MTs.
  • Co-immunoprecipitation and in vitro kinase activity of these tumors revealed that these cell cycle entities are functional.
  • Collectively, these results support the involvement of cyclin E1·CDK2 in centrosome overduplication during each stage of E(2)-induced mammary tumorigenesis.
  • [MeSH-major] Carcinoma, Ductal, Breast / metabolism. Cell Transformation, Neoplastic / metabolism. Cyclin E / biosynthesis. Cyclin-Dependent Kinase 2 / biosynthesis. Mammary Neoplasms, Experimental / metabolism
  • [MeSH-minor] Animals. Blotting, Western. Carcinoma in Situ / chemically induced. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Centrosome / metabolism. Centrosome / pathology. Estrogens / toxicity. Female. Immunoprecipitation. Precancerous Conditions / chemically induced. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Rats. Rats, Inbred ACI. Real-Time Polymerase Chain Reaction. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2001 Jul 13;106(1):95-104 [11461705.001]
  • [Cites] Int J Cancer. 1996 Aug 22;69(4):247-53 [8797862.001]
  • [Cites] Cancer Res. 1994 Jan 15;54(2):380-5 [7903908.001]
  • [Cites] Oncogene. 2004 Mar 25;23(13):2379-84 [14767474.001]
  • [Cites] Cancer. 1990 Sep 15;66(6 Suppl):1326-35 [2205361.001]
  • [Cites] Histopathology. 1998 Dec;33(6):522-30 [9870146.001]
  • [Cites] J Biol Chem. 2005 Jan 7;280(1):768-76 [15509582.001]
  • [Cites] J Cell Sci. 2008 Oct 1;121(Pt 19):3224-32 [18799789.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):7355-60 [16849587.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3198-208 [15126360.001]
  • [Cites] Oncogene. 2007 Sep 20;26(43):6280-8 [17438528.001]
  • [Cites] Cell. 2008 Jun 13;133(6):1032-42 [18555779.001]
  • [Cites] J Biomed Biotechnol. 2005;2005(3):248-53 [16192683.001]
  • [Cites] Curr Biol. 1999 Apr 22;9(8):429-32 [10226033.001]
  • [Cites] Cancer Res. 1999 May 1;59(9):2041-4 [10232583.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Feb 1;90(3):1112-6 [8430082.001]
  • [Cites] Breast Cancer Res. 2002;4(4):145-7 [12100739.001]
  • [Cites] Carcinogenesis. 2006 Mar;27(3):491-8 [16311245.001]
  • [Cites] Anal Cell Pathol. 2001;23(1):21-8 [11790856.001]
  • [Cites] Cancer. 1996 Aug 15;78(4):764-72 [8756370.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):28-34 [12506166.001]
  • [Cites] Adv Exp Med Biol. 2008;630:189-205 [18637492.001]
  • [Cites] Genes Cells. 2005 Jan;10(1):75-86 [15670215.001]
  • [Cites] J Pathol. 2003 Jul;200(3):375-82 [12845634.001]
  • [Cites] Oncogene. 1999 Mar 18;18(11):1983-91 [10208420.001]
  • [Cites] Oncogene. 1997 May 22;14(20):2373-81 [9188852.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):439-43 [17372238.001]
  • [Cites] Nature. 2001 Sep 20;413(6853):316-22 [11565034.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18123-8 [15601761.001]
  • [Cites] Biochim Biophys Acta. 2008 Sep;1786(1):15-23 [18472015.001]
  • [Cites] Cancer Metastasis Rev. 2003 Dec;22(4):451-64 [12884918.001]
  • [Cites] Mol Carcinog. 2002 Jan;33(1):56-65 [11807958.001]
  • [Cites] Br J Cancer. 1997;76(10):1288-92 [9374373.001]
  • [Cites] Science. 1999 Feb 5;283(5403):851-4 [9933170.001]
  • [Cites] Int J Cancer. 1996 Jan 26;65(3):323-7 [8575852.001]
  • [Cites] Cell. 2000 Sep 29;103(1):127-40 [11051553.001]
  • [Cites] Pharmacol Ther. 2006 Sep;111(3):974-84 [16603252.001]
  • [Cites] Cell Cycle. 2005 Feb;4(2):330-8 [15684604.001]
  • [Cites] Dev Cell. 2002 Sep;3(3):339-50 [12361598.001]
  • [Cites] Nat Rev Cancer. 2005 Jan;5(1):42-50 [15630414.001]
  • [Cites] Mol Carcinog. 1998 Nov;23(3):185-92 [9833779.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):1978-83 [11830638.001]
  • (PMID = 21761349.001).
  • [ISSN] 1868-8500
  • [Journal-full-title] Hormones & cancer
  • [ISO-abbreviation] Horm Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin E; 0 / Estrogens; EC 2.7.11.22 / Cyclin-Dependent Kinase 2
  •  go-up   go-down


33. Joseph DA, Miller JW, Wu X, Chen VW, Morris CR, Goodman MT, Villalon-Gomez JM, Williams MA, Cress RD: Understanding the burden of human papillomavirus-associated anal cancers in the US. Cancer; 2008 Nov 15;113(10 Suppl):2892-900
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Understanding the burden of human papillomavirus-associated anal cancers in the US.
  • BACKGROUND: Anal cancer is an uncommon malignancy in the US; up to 93% of anal cancers are associated with human papillomavirus.
  • METHODS: Cases diagnosed between 1998 and 2003 from 39 population-based cancer registries were analyzed.
  • The following anal cancer histologies were included in the analysis: squamous cell, adenocarcinoma, and small cell/neuroendocrine carcinomas.
  • RESULTS: From 1998 through 2003, the annual age-adjusted invasive anal cancer incidence rate was 1.5 per 100,000 persons.
  • Squamous cell carcinoma (SCC) was the most common histology overall, accounting for 18,105 of 21,395 (84.6%) cases of anal cancer.
  • Incidence rates of anal SCC increased 2.6% per year on average.
  • The majority of SCC cases were diagnosed at the in situ or localized stage (58.1%).
  • API were more likely to be diagnosed with regional or distant stage disease than were other racial/ethnic groups (27.5% and 11.8%, respectively).
  • CONCLUSIONS: Rates of anal SCC varied by sex, race, and ethnicity.
  • A higher proportion of API were diagnosed at regional/distant stage.
  • Continued surveillance and additional research are needed to assess the potential impact of the HPV vaccine on the anal cancer burden in the US.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Cancer. 2000 Mar 15;88(6):1464-9 [10717631.001]
  • [Cites] Clin Infect Dis. 2002 Nov 1;35(9):1127-34 [12384848.001]
  • [Cites] AIDS. 2003 Feb 14;17(3):311-20 [12556684.001]
  • [Cites] Prev Med. 2003 May;36(5):555-60 [12689800.001]
  • [Cites] Dis Colon Rectum. 2003 Nov;46(11):1517-23; discussion 1523-4; author reply 1524 [14605572.001]
  • [Cites] Cancer Causes Control. 2003 Nov;14(9):837-46 [14682441.001]
  • [Cites] Lancet Oncol. 2004 Mar;5(3):149-57 [15003197.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]
  • [Cites] Gastroenterology. 1988 Jul;95(1):107-11 [2836255.001]
  • [Cites] Am J Epidemiol. 1992 Jan 15;135(2):180-9 [1311142.001]
  • [Cites] Am J Epidemiol. 1992 Jul 1;136(1):54-8 [1329500.001]
  • [Cites] Am J Epidemiol. 1994 Apr 15;139(8):772-80 [8178790.001]
  • [Cites] Am J Epidemiol. 1994 Jul 1;140(1):12-9 [8017399.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] Semin Cancer Biol. 1998 Aug;8(4):307-13 [9870037.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):753-7 [9973228.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] Clin Infect Dis. 2006 Jul 15;43(2):223-33 [16779751.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2006 Oct 27;55(42):1145-8 [17065979.001]
  • [Cites] Stat Methods Med Res. 2006 Dec;15(6):547-69 [17260923.001]
  • [Cites] Lancet Oncol. 2007 Apr;8(4):311-6 [17395104.001]
  • [Cites] Am J Surg Pathol. 2007 Jun;31(6):919-25 [17527081.001]
  • [Cites] Clin Microbiol Rev. 2007 Jul;20(3):478-88, table of contents [17630336.001]
  • [Cites] Sex Transm Infect. 2007 Jul;83(4):257-66 [17664359.001]
  • [Cites] Cancer Causes Control. 2007 Dec;18(10):1175-86 [17805982.001]
  • [Cites] Cancer. 2008 Nov 15;113(10 Suppl):2841-54 [18980203.001]
  • [Cites] Dermatol Ther. 2005 Jan-Feb;18(1):67-76 [15842614.001]
  • [Cites] Dan Med Bull. 2002 Aug;49(3):194-209 [12238281.001]
  • (PMID = 18980293.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] None / None / / N01 PC035137; United States / NCCDPHP CDC HHS / DP / U50 DP424071; United States / NCI NIH HHS / PC / N01 PC035137; United States / NCCDPHP CDC HHS / DP / U50 DP424071-04
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS104103; NLM/ PMC2729501
  •  go-up   go-down


34. Chiappa A, Biffi R, Zbar AP, Luca F, Crotti C, Bertani E, Biella F, Zampino G, Orecchia R, Fazio N, Venturino M, Crosta C, Pruneri GC, Grassi C, Andreoni B: Results of treatment of distal rectal carcinoma since the introduction of total mesorectal excision: a single unit experience, 1994-2003. Int J Colorectal Dis; 2005 May;20(3):221-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of treatment of distal rectal carcinoma since the introduction of total mesorectal excision: a single unit experience, 1994-2003.
  • BACKGROUND AND AIMS: This study reviewed the results of surgery for distal rectal cancer (where the tumour was within 6 cm of the anal verge) following the introduction of total mesorectal excision for rectal cancer in one institution.
  • PATIENTS AND METHODS: One hundred and fifty-three patients who had undergone elective curative surgical resection of rectal cancer within 6 cm of the anal verge were included.
  • On multivariate analysis type of surgery (P=0.025) and tumour stage (P=0.043), were associated with local recurrence, but only stage was a significant prognosticator of overall survival (P=0.0006).
  • CONCLUSION: With the practice of total mesorectal excision, APR was still necessary in 40% of patients with rectal cancer within 6 cm of the anal verge.
  • [MeSH-major] Carcinoma / surgery. Digestive System Surgical Procedures / methods. Postoperative Care / methods. Rectal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2002 Oct;26(10):1272-6 [12205546.001]
  • [Cites] Br J Surg. 1995 Aug;82(8):1031-3 [7648142.001]
  • [Cites] Dis Colon Rectum. 1997 Jul;40(7):747-51 [9221846.001]
  • [Cites] Tech Coloproctol. 2001 Aug;5(2):97-102 [11862566.001]
  • [Cites] Arch Surg. 1998 Aug;133(8):894-9 [9711965.001]
  • [Cites] Dis Colon Rectum. 1990 Feb;33(2):117-21 [2298097.001]
  • [Cites] Br J Surg. 1996 Mar;83(3):375-9 [8665198.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Br J Surg. 1985 Jan;72(1):34-7 [3967128.001]
  • [Cites] Br J Surg. 2002 Sep;89(9):1142-9 [12190680.001]
  • [Cites] Lancet. 2000 Jul 8;356(9224):93-6 [10963244.001]
  • [Cites] Dis Colon Rectum. 2001 Apr;44(4):473-83; discussion 483-6 [11330574.001]
  • [Cites] N Engl J Med. 1985 Jun 20;312(25):1604-8 [4000199.001]
  • [Cites] Dis Colon Rectum. 2001 Jul;44(7):947-54 [11496074.001]
  • [Cites] Dis Colon Rectum. 1997 Jan;40(1):117 [9102254.001]
  • [Cites] Dis Colon Rectum. 1995 Aug;38(8):799-802 [7543403.001]
  • [Cites] Dis Colon Rectum. 1991 Apr;34(4):317-22 [2007349.001]
  • [Cites] Br J Surg. 2003 Aug;90(8):974-80 [12905551.001]
  • [Cites] Aust N Z J Surg. 2000 Oct;70(10 ):704-9 [11021483.001]
  • [Cites] Br J Surg. 2001 Nov;88(11):1501-5 [11683749.001]
  • [Cites] Br J Surg. 1999 Sep;86(9):1164-70 [10504371.001]
  • [Cites] Eur J Surg Oncol. 2000 Dec;26(8):751-7 [11087640.001]
  • [Cites] Eur J Surg. 1996 Aug;162(8):643-8 [8891623.001]
  • [Cites] Br J Surg. 1984 Sep;71(9):659-63 [6478151.001]
  • [Cites] Dis Colon Rectum. 2000 Dec;43(12):1710-2 [11156455.001]
  • [Cites] Surgery. 1998 Oct;124(4):612-7; discussion 617-8 [9780979.001]
  • [Cites] Cancer. 1988 Apr 1;61(7):1408-16 [3345493.001]
  • [Cites] Dis Colon Rectum. 2002 Jul;45(7):857-66 [12130870.001]
  • [Cites] Eur J Surg Oncol. 2003 Apr;29(3):239-43 [12657233.001]
  • [Cites] Ann Surg Oncol. 2003 Jan-Feb;10(1):72-9 [12513964.001]
  • [Cites] Dis Colon Rectum. 1996 Mar;39(3):323-8 [8603556.001]
  • [Cites] Dis Colon Rectum. 1992 Mar;35(3):238-41 [1740068.001]
  • [Cites] Eur J Surg Oncol. 1995 Feb;21(1):11-5 [7851543.001]
  • [Cites] Eur J Surg Oncol. 1995 Dec;21(6):640-3 [8631412.001]
  • [Cites] Colorectal Dis. 2001 May;3(3):179-84 [12790986.001]
  • [Cites] Dis Colon Rectum. 2002 Jul;45(7):895-903 [12130878.001]
  • [Cites] Ann Surg. 1990 Jun;211(6):745-51; discussion 751-2 [2357137.001]
  • [Cites] Dis Colon Rectum. 1998 Aug;41(8):979-83 [9715152.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1261-6 [14515297.001]
  • [Cites] Ann Surg Oncol. 2003 Jan-Feb;10(1):80-5 [12513965.001]
  • [Cites] Chir Ital. 2003 May-Jun;55(3):333-44 [12872567.001]
  • [Cites] Br J Surg. 1999 Mar;86(3):379-84 [10201783.001]
  • [Cites] Dis Colon Rectum. 2004 Jan;47(1):48-58 [14719151.001]
  • [Cites] Br J Surg. 1998 Apr;85(4):526-9 [9607540.001]
  • (PMID = 15602647.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


35. Chen JJ, Yang BL, Zhang JX, Xu WP, Shao ZM, Wu J: The evaluation and optimization of intraoperative touch imprint cytology for sentinel lymph nodes in early-stage breast cancer in China. World J Surg; 2010 Oct;34(10):2325-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The evaluation and optimization of intraoperative touch imprint cytology for sentinel lymph nodes in early-stage breast cancer in China.
  • BACKGROUND: Accurate intraoperative diagnosis of sentinel lymph node (SLN) metastasis reduces the need for additional surgery in patients with involved nodes.
  • The present study evaluates the clinical value of multiple cross-sectional touch imprint cytology (TIC) as an intraoperative assessment for the diagnosis of SLN metastasis.
  • Serial sectioning of the SLNs at 100-microm intervals with hematoxylin-eosin (H&E) staining was used as the gold standard for pathological diagnosis.
  • Limiting intraoperative TIC to the first three harvested SLNs in the diagnosis of SLN metastasis may make this diagnostic procedure significantly cheaper and easier for pathologists to perform.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Histocytological Preparation Techniques / methods. Lymph Nodes / pathology. Sentinel Lymph Node Biopsy

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2008 May;247(5):839-42 [18438122.001]
  • [Cites] J Surg Oncol. 2004 Feb;85(2):82-6; discussion 87 [14755508.001]
  • [Cites] Mod Pathol. 2002 Nov;15(11):1140-7 [12429792.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):966-78 [10888772.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2002 Dec;10(4):296-303 [12607596.001]
  • [Cites] Eur J Surg Oncol. 2009 Sep;35(9):921-7 [19233602.001]
  • [Cites] J Surg Oncol. 2003 Oct;84(2):68-73 [14502779.001]
  • [Cites] Br J Surg. 1999 Oct;86(10):1346-8 [10540148.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):842-5 [12766591.001]
  • [Cites] Ann Surg. 2004 Jan;239(1):61-6 [14685101.001]
  • [Cites] Ann Surg Oncol. 2002 May;9(4):333-9 [11986184.001]
  • [Cites] Ann Surg Oncol. 2008 May;15(5):1309-15 [18253802.001]
  • [Cites] Anal Quant Cytol Histol. 2005 Aug;27(4):187-94 [16220829.001]
  • [Cites] Ann Surg Oncol. 2001 Aug;8(7):592-7 [11508621.001]
  • [Cites] ANZ J Surg. 2003 Aug;73(8):597-9 [12887528.001]
  • [Cites] Br J Surg. 2000 May;87(5):597-601 [10792316.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1068-80 [16106479.001]
  • [Cites] Eur J Cancer. 2006 Mar;42(5):617-20 [16446084.001]
  • [Cites] World J Surg. 2002 Nov;26(11):1365-9 [12297929.001]
  • [Cites] Eur Radiol. 2008 Sep;18(9):1761-73 [18414872.001]
  • [Cites] Am Surg. 2003 May;69(5):419-23 [12769215.001]
  • [Cites] Ann Surg Oncol. 2003 Dec;10(10):1166-70 [14654472.001]
  • [Cites] Adv Anat Pathol. 2002 Jul;9(4):233-43 [12072814.001]
  • [Cites] N Engl J Med. 2003 Aug 7;349(6):546-53 [12904519.001]
  • [Cites] Am Surg. 2001 Jan;67(1):86-91 [11206905.001]
  • [Cites] Ann Surg Oncol. 1998 Dec;5(8):689-94 [9869514.001]
  • [Cites] Ann Surg Oncol. 2004 Aug;11(8):747-50 [15249334.001]
  • (PMID = 20567971.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


36. El Badry AA, El-Fadle AA, El-Balshy AL: Tissue inhibitor of matrix metalloproteinase-2 in nasopharyngeal carcinoma. MedGenMed; 2007;9(3):3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue inhibitor of matrix metalloproteinase-2 in nasopharyngeal carcinoma.
  • The present study was designed to clarify the role of TIMP-2 in nasopharyngeal carcinoma (NPC) patients and to evaluate its importance relative to clinicopathologic parameters.
  • Clinically, in accordance with TNM classification (T: tumor size, N: lymph node involvement, M: distant metastasis), 8 cases were diagnosed as stage II, 12 as stage III, and 10 cases as stage IV; however, pathologic typing with use of the World Health Organization (WHO) classification revealed the presence of 9 specimens of squamous cell carcinoma (WHO type 1), 6 cases of nonkeratinizing carcinoma (WHO type 2), and 15 cases of undifferentiated carcinoma (WHO type 3).
  • In addition, there was a significant positive correlation between TIMP-2 protein positivity and either the clinical staging or the histopathologic typing (P < .01) using Chi-square test (x(2)), suggesting that TIMP-2 can be used as a marker of the severity of NPC.Accordingly, we can assume that TIMP-2 may play a role in regional lymph node and/or distant metastasis and in progression of squamous cell carcinoma.
  • [MeSH-major] Carcinoma / chemistry. Carcinoma / enzymology. Nasopharyngeal Neoplasms / chemistry. Nasopharyngeal Neoplasms / enzymology. Tissue Inhibitor of Metalloproteinase-2 / analysis

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1999 Nov;189(3):300-8 [10547590.001]
  • [Cites] Am J Clin Pathol. 1993 Jan;99(1):18-23 [8422010.001]
  • [Cites] Adv Exp Med Biol. 2000;465:469-83 [10810650.001]
  • [Cites] Br J Cancer. 2000 Jul;83(2):215-8 [10901373.001]
  • [Cites] Hum Pathol. 2000 Aug;31(8):895-904 [10987249.001]
  • [Cites] Int J Oncol. 2000 Dec;17(6):1099-105 [11078794.001]
  • [Cites] Int J Cancer. 2001 Jan 20;95(1):44-50 [11241310.001]
  • [Cites] J Med Invest. 2001 Feb;48(1-2):31-43 [11286015.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Jul;127(7):813-20 [11448356.001]
  • [Cites] Int J Colorectal Dis. 2001 Jun;16(3):133-40 [11459286.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3113-9 [11595703.001]
  • [Cites] Mod Pathol. 2002 Jan;15(1):26-34 [11796838.001]
  • [Cites] Isr Med Assoc J. 2002 Apr;4(4):247-51 [12001695.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 28;99(11):7414-9 [12032297.001]
  • [Cites] Ai Zheng. 2002 Jan;21(1):91-4 [12500407.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Otolaryngol Head Neck Surg. 1983 Jun;91(3):255-62 [6308537.001]
  • [Cites] J Biol Chem. 1989 Oct 15;264(29):17374-8 [2793861.001]
  • [Cites] Int J Cancer. 1994 Nov 1;59(3):339-44 [7927938.001]
  • [Cites] J Biol Chem. 1995 Mar 10;270(10):5331-8 [7890645.001]
  • [Cites] Cancer Res. 1996 Apr 1;56(7):1654-9 [8603416.001]
  • [Cites] FEBS Lett. 1996 May 6;385(3):238-40 [8647259.001]
  • [Cites] Cancer Res. 1996 Jun 15;56(12):2707-10 [8665498.001]
  • [Cites] Cancer. 1997 Jan 1;79(1):139-44 [8988738.001]
  • [Cites] Eur J Cell Biol. 1997 Oct;74(2):111-22 [9352216.001]
  • [Cites] Nat Genet. 1997 Dec;17(4):439-44 [9398846.001]
  • [Cites] Br J Cancer. 1998 Feb;77(4):650-5 [9484825.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1359-66 [9529029.001]
  • [Cites] Clin Cancer Res. 1997 Sep;3(9):1623-8 [9815852.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):467-73 [9927064.001]
  • [Cites] Anticancer Res. 1999 Mar-Apr;19(2C):1589-92 [10365151.001]
  • [Cites] J Biol Chem. 1999 Jul 30;274(31):21491-4 [10419448.001]
  • [Cites] Head Neck. 1999 Oct;21(7):627-38 [10487950.001]
  • [Cites] J Biol Chem. 1991 Sep 5;266(25):16485-90 [1653238.001]
  • [Cites] Anticancer Res. 2000 Mar-Apr;20(2B):1085-91 [10810401.001]
  • (PMID = 18092010.001).
  • [ISSN] 1531-0132
  • [Journal-full-title] MedGenMed : Medscape general medicine
  • [ISO-abbreviation] MedGenMed
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2
  • [Other-IDs] NLM/ PMC2100075
  •  go-up   go-down


37. Garrett K, Kalady MF: Anal neoplasms. Surg Clin North Am; 2010 Feb;90(1):147-61, Table of Contents
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal neoplasms.
  • A variety of lesions comprise tumors of the anal canal, with carcinoma in situ and epidermoid cancers being the most common.
  • Less common anal neoplasms include adenocarcinoma, melanoma, gastrointestinal stromal cell tumors, neuroendocrine tumors, and Buschke-Lowenstein tumors.
  • In this article different tumors and management of each, including a brief review of local excision for rectal cancer, are discussed in turn.
  • [MeSH-major] Anus Neoplasms / surgery
  • [MeSH-minor] Carcinoma in Situ / pathology. Carcinoma, Squamous Cell / pathology. Carcinoma, Verrucous / diagnosis. Carcinoma, Verrucous / pathology. Humans. Intestinal Mucosa / pathology. Neoplasm Recurrence, Local / surgery. Prognosis. Rectal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20109639.001).
  • [ISSN] 1558-3171
  • [Journal-full-title] The Surgical clinics of North America
  • [ISO-abbreviation] Surg. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 105
  •  go-up   go-down


38. Lefevre JH, Parc Y, Kernéis S, Shields C, Touboul E, Chaouat M, Tiret E: Abdomino-perineal resection for anal cancer: impact of a vertical rectus abdominis myocutaneus flap on survival, recurrence, morbidity, and wound healing. Ann Surg; 2009 Nov;250(5):707-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abdomino-perineal resection for anal cancer: impact of a vertical rectus abdominis myocutaneus flap on survival, recurrence, morbidity, and wound healing.
  • OBJECTIVES: To evaluate the results of a vertical rectus abdominis myocutaneus (VRAM) flap after abdomino-perineal resection (APR) for anal cancer (AC).
  • The groups (VRAM vs. No VRAM) differed in age at surgery (56.3 vs. 62.1; P = 0.0263); administration of chemotherapy in addition to radiotherapy (81% vs. 59%; P = 0.0218); and stage (ypT3-T4 67.6% vs. 38.4%; P = 0.0394).
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Postoperative Complications. Surgical Flaps. Wound Healing


39. Hohenberger W, Merkel S, Matzel K, Bittorf B, Papadopoulos T, Göhl J: The influence of abdomino-peranal (intersphincteric) resection of lower third rectal carcinoma on the rates of sphincter preservation and locoregional recurrence. Colorectal Dis; 2006 Jan;8(1):23-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The influence of abdomino-peranal (intersphincteric) resection of lower third rectal carcinoma on the rates of sphincter preservation and locoregional recurrence.
  • PATIENTS AND METHODS: The data of 476 patients with a carcinoma in the lower third of the rectum who underwent primary treatment for stage I-III disease by low anterior resection, abdomino-peranal (intersphincteric) resection or abdominoperineal excision between 1985 and 2001 were analysed.
  • The cancer-related 5-year survival rate was not altered by intersphincteric resection.
  • [MeSH-major] Anal Canal / surgery. Carcinoma / surgery. Colectomy / methods. Neoplasm Recurrence, Local / epidemiology. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16519634.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


40. Ascani G, Balercia P, Messi M, Lupi L, Goteri G, Filosa A, Stramazzotti D, Pieramici T, Rubini C: Angiogenesis in oral squamous cell carcinoma. Acta Otorhinolaryngol Ital; 2005 Feb;25(1):13-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenesis in oral squamous cell carcinoma.
  • Based on these results, microvessel density was evaluated, in the present study, in 64 cases of squamous cell carcinoma of the oral cavity, using immunohistochemical analysis with anti-CD34 monoclonal antibody.
  • Possible correlations between microvessel density and clinico-pathological parameters were analysed, such as: age, sex, tumour localization and size, TNM stage and histological grading.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Mouth Neoplasms / pathology. Neovascularization, Pathologic / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2000 Apr;6(4):389-95 [10742145.001]
  • [Cites] J Pathol. 1998 Feb;184(2):119-22 [9602700.001]
  • [Cites] Anal Cell Pathol. 2001;22(4):183-92 [11564894.001]
  • [Cites] J Exp Clin Cancer Res. 2001 Dec;20(4):463-8 [11876537.001]
  • [Cites] Head Neck. 2002 Jul;24(7):643-50 [12112537.001]
  • [Cites] Int J Oral Maxillofac Surg. 2004 Jan;33(1):2-7 [14690652.001]
  • [Cites] Sci Am. 1976 May;234(5):58-64, 70-3 [1273568.001]
  • [Cites] Am J Pathol. 1988 Nov;133(2):419-23 [3189515.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • [Cites] Lancet. 1992 Jul 18;340(8812):145-6 [1378165.001]
  • [Cites] Eur J Cancer. 1993;29A(8):1141-5 [8390846.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):401-9 [7688183.001]
  • [Cites] Cancer. 1994 Feb 1;73(3):678-87 [7507798.001]
  • [Cites] J Clin Oncol. 1994 Mar;12(3):454-66 [7509851.001]
  • [Cites] Otolaryngol Head Neck Surg. 1994 Oct;111(4):417-22 [7524005.001]
  • [Cites] Am J Surg. 1994 Nov;168(5):373-80 [7526718.001]
  • [Cites] J Natl Cancer Inst. 1995 Jul 5;87(13):997-1008 [7543156.001]
  • [Cites] Anticancer Res. 1995 Jul-Aug;15(4):1417-22 [7544566.001]
  • [Cites] Br J Oral Maxillofac Surg. 1996 Feb;34(1):37-41 [8645680.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1996 Aug;122(8):865-8 [8703391.001]
  • [Cites] Head Neck. 1996 Jul-Aug;18(4):343-6 [8780945.001]
  • [Cites] Head Neck. 1997 Jul;19(4):276-80 [9213105.001]
  • [Cites] J Pathol. 1997 Sep;183(1):39-43 [9370945.001]
  • [Cites] Oral Oncol. 1997 Sep;33(5):369-74 [9415339.001]
  • [Cites] Lab Invest. 1997 Dec;77(6):659-64 [9426404.001]
  • [Cites] Annu Rev Med. 1998;49:407-24 [9509272.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2821-8 [10914730.001]
  • (PMID = 16080310.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD31
  • [Other-IDs] NLM/ PMC2639850
  •  go-up   go-down


41. Qian HG, Shen J, Ma H, Ma HC, Su YH, Hao CY, Xing BC, Huang XF, Shou CC: Preliminary study on proteomics of gastric carcinoma and its clinical significance. World J Gastroenterol; 2005 Oct 28;11(40):6249-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary study on proteomics of gastric carcinoma and its clinical significance.
  • AIM: To explore the preliminary identification of serum protein pattern models that may be novel potential biomarkers in the detection of gastric cancer.
  • METHODS: A total of 130 serum samples, including 70 from patients with gastric cancer and 60 from healthy adults, were detected by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry (SELDI-TOF-MS).
  • Thirty serum samples of gastric cancer patients and 30 serum samples of healthy adults were grouped into the training group to build models, and the other 70 samples were used to test and evaluate the models.
  • The samples of the test group were judged only with their peaks' height and were separated into cancer group or healthy control group by BPS automatically and the judgments were checked with the histopathologic diagnosis of the samples.
  • Among them, nine mass peaks showed increased expression in patients with gastric cancer.
  • Analyzed by BPS, two peaks were chosen to build the model for gastric cancer detection.
  • Stage I/II gastric cancer samples of the test group were all judged correctly.
  • CONCLUSION: The novel biomarkers in serum and the established model could be potentially used in the detection of gastric cancer.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16419150.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC4320325
  •  go-up   go-down


42. Ferrigno R, Nakamura RA, Dos Santos Novaes PE, Pellizzon AC, Maia MA, Fogarolli RC, Salvajoli JV, Filho WJ, Lopes A: Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness. Int J Radiat Oncol Biol Phys; 2005 Mar 15;61(4):1136-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness.
  • PURPOSE: This retrospective analysis reports the results on patients with anal canal carcinoma treated by combined radiotherapy and chemotherapy.
  • METHODS AND MATERIALS: Between March 1993 and December 2001, 43 patients with anal canal carcinoma were treated with radiochemotherapy at the Hospital do Cancer A.C. Camargo.
  • Stage distribution was as follows: I, 3 (7%); II, 23 (53.5%); IIIA, 8 (18.6%); and IIIB, 9 (21%).
  • Patient's age, tumor stage, overall treatment time, and RT dose at primary tumor were variables analyzed for survival and local control.
  • Overall survival according to clinical stage was as follows: I, 100%; II, 82%; IIIA, 73%; and IIIB, 18% (p = 0.0049).
  • CONCLUSIONS: This analysis suggests that the treatment scheme employed was effective for anal sphincter preservation and local control; however, the incidence of distant metastases was relatively high.
  • The clinical stage was the main prognostic factor for overall survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15752894.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


43. Asahi T, Kondo H, Masuda M, Nishino H, Aratani Y, Naito Y, Yoshikawa T, Hisaka S, Kato Y, Osawa T: Chemical and immunochemical detection of 8-halogenated deoxyguanosines at early stage inflammation. J Biol Chem; 2010 Mar 19;285(12):9282-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemical and immunochemical detection of 8-halogenated deoxyguanosines at early stage inflammation.
  • Interestingly, positive mAb8B3 antibody staining was observed in liver tissue from hepatocellular carcinoma patients but not in liver tissue from human cirrhosis patients.

  • Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .
  • Hazardous Substances Data Bank. L-TYROSINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1631-6 [11172002.001]
  • [Cites] J Clin Invest. 1996 Sep 15;98(6):1283-9 [8823292.001]
  • [Cites] Lab Invest. 1997 Mar;76(3):365-74 [9121119.001]
  • [Cites] J Clin Invest. 1997 May 1;99(9):2075-81 [9151778.001]
  • [Cites] J Lipid Res. 1997 Jul;38(7):1334-46 [9254060.001]
  • [Cites] Nature. 1998 Jan 22;391(6665):393-7 [9450756.001]
  • [Cites] Carcinogenesis. 1998 Oct;19(10):1809-14 [9806163.001]
  • [Cites] Diabetes. 1999 Jan;48(1):1-9 [9892215.001]
  • [Cites] Biochemistry. 1998 Dec 22;37(51):17923-30 [9922160.001]
  • [Cites] Infect Immun. 1999 Apr;67(4):1828-36 [10085024.001]
  • [Cites] J Biol Chem. 1999 Jul 16;274(29):20406-14 [10400665.001]
  • [Cites] J Biol Chem. 2004 Dec 3;279(49):51241-9 [15364942.001]
  • [Cites] Free Radic Biol Med. 2005 Jan 1;38(1):24-31 [15589368.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Nov 15;827(1):26-31 [16260376.001]
  • [Cites] J Biol Chem. 2006 Feb 10;281(6):3096-104 [16326702.001]
  • [Cites] Basic Clin Pharmacol Toxicol. 2006 May;98(5):496-502 [16635109.001]
  • [Cites] Free Radic Biol Med. 2006 Aug 15;41(4):620-6 [16863995.001]
  • [Cites] J Biol Chem. 1999 Nov 19;274(47):33440-8 [10559226.001]
  • [Cites] Nature. 2000 Feb 24;403(6772):859-66 [10706276.001]
  • [Cites] Biochemistry. 2001 Feb 20;40(7):2041-51 [11329271.001]
  • [Cites] Biochemistry. 2001 Feb 20;40(7):2052-9 [11329272.001]
  • [Cites] Nucleosides Nucleotides Nucleic Acids. 2001 Mar;20(3):251-60 [11393401.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):11961-6 [11593004.001]
  • [Cites] J Biol Chem. 2001 Nov 2;276(44):40486-96 [11533049.001]
  • [Cites] Free Radic Biol Med. 2001 Dec 1;31(11):1341-51 [11728805.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2081-8 [11733358.001]
  • [Cites] FEBS Lett. 2002 Apr 10;516(1-3):67-70 [11959105.001]
  • [Cites] Toxicology. 2002 Aug 1;177(1):11-22 [12126792.001]
  • [Cites] J Biol Chem. 2002 Nov 29;277(48):46116-22 [12359714.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):685-90 [12522148.001]
  • [Cites] J Biol Chem. 2003 Mar 14;278(11):8942-50 [12643282.001]
  • [Cites] Anal Biochem. 2003 Jun 15;317(2):201-9 [12758258.001]
  • [Cites] J Biol Chem. 2003 Jun 27;278(26):23522-8 [12707270.001]
  • [Cites] J Biol Chem. 2003 Sep 19;278(38):36365-72 [12869568.001]
  • [Cites] J Virol. 2004 Aug;78(16):8709-19 [15280479.001]
  • [Cites] Blood. 1990 Aug 15;76(4):655-63 [2200535.001]
  • [Cites] J Biol Chem. 1991 May 15;266(14):9050-4 [1851162.001]
  • [Cites] J Biol Chem. 1993 Feb 25;268(6):4069-77 [8382689.001]
  • [Cites] Gastroenterol Jpn. 1993 Aug;28(4):541-6 [8397132.001]
  • [Cites] Mutat Res. 1994 Mar 1;305(2):253-64 [7510036.001]
  • [Cites] Biol Chem Hoppe Seyler. 1994 Feb;375(2):81-8 [8192861.001]
  • [Cites] J Biol Chem. 1995 Jul 14;270(28):16542-8 [7622459.001]
  • [Cites] Biochem J. 1996 Jan 1;313 ( Pt 1):17-29 [8546679.001]
  • [Cites] Neuro Oncol. 2001 Apr;3(2):73-81 [11296483.001]
  • (PMID = 20081197.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Halogens; 0 / Lipopolysaccharides; 3604-79-3 / 3-nitrotyrosine; 42HK56048U / Tyrosine; 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; EC 1.11.1.7 / Peroxidase; G9481N71RO / Deoxyguanosine
  • [Other-IDs] NLM/ PMC2838346
  •  go-up   go-down


44. Saleh F, Abdeen S: Pathobiological features of breast tumours in the State of Kuwait: a comprehensive analysis. J Carcinog; 2007;6:12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Breast cancer accounts for 30.3% of all cancer types in Kuwaiti women.
  • Grading of invasive carcinomas was done according to the modified Bloom-Richardson-Elston's method, and tumour stage was determined according to the criteria set by the American Joint Committee on Cancer.
  • They were mostly grade II or III, sized 2-5 or > 5 cm, had absent or scanty tumour lymphocytes, and were stage II or III.
  • The in situ tumours were mainly ductal carcinoma (DCIS) of which comedo and cribriform were the major histological subtypes.
  • CONCLUSION: Breast cancer in Kuwait seems to be more aggressive than what is currently seen in Europe, North America, Australia, and parts of Asia.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 1998 Feb;11(2):155-68 [9504686.001]
  • [Cites] J Surg Oncol. 2004 Jun 1;86(3):134-40 [15170651.001]
  • [Cites] Breast Cancer Res Treat. 1998;51(3):195-208 [10068079.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):26-35 [15332092.001]
  • [Cites] Eur J Cancer Prev. 2004 Aug;13(4):307-17 [15554559.001]
  • [Cites] Am Surg. 2005 Jan;71(1):22-7; discussion 27-8 [15757052.001]
  • [Cites] Kaohsiung J Med Sci. 2005 May;21(5):197-202 [15960065.001]
  • [Cites] Breast Cancer Res. 2005;7(4):R541-54 [15987461.001]
  • [Cites] Br J Dermatol. 2005 Jul;153(1):18-21 [16029321.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3c):2535-42 [16080489.001]
  • [Cites] J Reprod Immunol. 2005 Oct;67(1-2):35-50 [16111767.001]
  • [Cites] Breast Cancer Res. 2005;7(5):R598-604 [16168103.001]
  • [Cites] Acta Oncol. 1990;29(7):931-4 [1979748.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):944-8 [1988136.001]
  • [Cites] Acta Oncol. 1990;29(2):129-35 [2334566.001]
  • [Cites] Acta Oncol. 1989;28(6):807-10 [2611034.001]
  • [Cites] Aust N Z J Med. 1978 Dec;8(6):630-8 [285684.001]
  • [Cites] BMJ. 1988 Oct 15;297(6654):943-8 [3142562.001]
  • [Cites] Acta Pathol Jpn. 1984 Mar;34(2):229-39 [6331061.001]
  • [Cites] J Clin Oncol. 1984 Oct;2(10):1102-9 [6491696.001]
  • [Cites] Hum Pathol. 1983 Apr;14(4):368-72 [6832775.001]
  • [Cites] Hum Pathol. 1995 Aug;26(8):873-9 [7635449.001]
  • [Cites] Breast Cancer Res Treat. 1995 Aug;35(2):201-10 [7647342.001]
  • [Cites] Semin Diagn Pathol. 1994 Aug;11(3):208-14 [7831532.001]
  • [Cites] Anal Quant Cytol Histol. 1994 Jun;16(3):203-10 [7916848.001]
  • [Cites] Surgery. 1994 Oct;116(4):605-8; discussion 608-9 [7940156.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):23-33 [8083119.001]
  • [Cites] Br J Cancer. 1993 Jul;68(1):156-61 [8100443.001]
  • [Cites] Hematol Oncol Clin North Am. 1994 Feb;8(1):73-100 [8150784.001]
  • [Cites] Am J Surg. 1993 Mar;165(3):307-11 [8447534.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2894-904 [9256133.001]
  • [Cites] AJR Am J Roentgenol. 1998 Jan;170(1):97-104 [9423608.001]
  • [Cites] Stem Cells. 1998;16(6):413-28 [9831867.001]
  • [Cites] Oncol Rep. 1999 Jan-Feb;6(1):135-8 [9864416.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):2011-7 [10213514.001]
  • [Cites] Ontogenez. 1999 Mar-Apr;30(2):130-3 [10368823.001]
  • [Cites] Mod Pathol. 1999 Aug;12(8):827-34 [10463486.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Oct;8(10):855-61 [10548312.001]
  • [Cites] Oncol Rep. 2000 Mar-Apr;7(2):295-8 [10671674.001]
  • [Cites] Am J Surg. 2000 Feb;179(2):81-5 [10773138.001]
  • [Cites] J Clin Pathol. 2000 Sep;53(9):688-96 [11041059.001]
  • [Cites] Int J Cancer. 2002 Apr 10;98(5):754-60 [11920647.001]
  • [Cites] Oncol Rep. 2002 Sep-Oct;9(5):1053-7 [12168072.001]
  • [Cites] Breast Cancer Res Treat. 2002 Dec;76(3):221-36 [12462383.001]
  • [Cites] Eur J Cancer. 2003 Mar;39(5):622-30 [12628841.001]
  • [Cites] Jpn J Clin Oncol. 2003 Feb;33(2):61-7 [12629055.001]
  • [Cites] Oncol Rep. 2003 Sep-Oct;10(5):1321-8 [12883701.001]
  • [Cites] Endocr Rev. 1992 Feb;13(1):3-17 [1313356.001]
  • [Cites] Br J Cancer. 1992 Oct;66(4):610-3 [1419596.001]
  • [Cites] Curr Opin Obstet Gynecol. 2004 Feb;16(1):49-55 [15128008.001]
  • [Cites] Breast Cancer Res Treat. 1998;52(1-3):305-19 [10066089.001]
  • (PMID = 17892570.001).
  • [ISSN] 1477-3163
  • [Journal-full-title] Journal of carcinogenesis
  • [ISO-abbreviation] J Carcinog
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2169224
  •  go-up   go-down


45. Selvindos PB, Ho YH: Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis. Dis Colon Rectum; 2008 Nov;51(11):1710-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis.
  • PURPOSE: Optimal treatment of mid to distal rectal cancers includes total mesorectal excision for oncologic clearance and, where reanastomosis is feasible, a colonic J-pouch-anal anastomosis improves bowel function.
  • Bowel continuity was restored by an intracoporeal double-cross stapled colonic J-pouch-anal anastomosis, but where not possible a coloplasty with pull-through handsewn coloanal anastomosis was performed.
  • The indications were adenocarcinoma (n = 51), squamous-cell carcinoma of rectum (n = 1), dermoid tumor of mesorectum (n = 1), large villous adenoma (n = 1), and carcinoid with local lymph node metastases (n = 1).
  • The adenocarcinomas were a median distance of 6 (3-12) cm from the anal verge.
  • The histologic grading or the adenocarcinoma patients were: Stage I, n = 14; Stage II, n = 23; Stage III, n = 11; Stage IV, n = 3.
  • The level of the coloanal anastomosis was a median 3.5 (0-4.5) cm from the anal verge; a coloanal pull-through anastomosis was required in one patient who had a distal cancer.
  • Four other patients had smaller pelvic collections that resolved with antibiotics; pelvic collections were associated with advanced stage of cancer (P = 0.047).
  • This brought the rectum proximally and anteriorly, aiding with the laparoscopic stapler transection of the distal rectum, especially if the cancer was distal, the patient was obese, and the pelvis was narrow.
  • Further randomized, controlled studies that include assessing five-year cancer survival/recurrence, pelvic nerve dysfunction, and bowel function are needed before laparoscopic ultralow anterior resection becomes widely accepted.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Colonic Pouches. Laparoscopy / methods. Proctocolectomy, Restorative / methods. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18679748.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Interactive Tutorial
  • [Publication-country] United States
  •  go-up   go-down


46. Liang B, Wang S, Zhu XG, Yu YX, Cui ZR, Yu YZ: Increased expression of mitogen-activated protein kinase and its upstream regulating signal in human gastric cancer. World J Gastroenterol; 2005 Feb 7;11(5):623-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of mitogen-activated protein kinase and its upstream regulating signal in human gastric cancer.
  • AIM: To investigate the expression of mitogen-activated protein kinases (MAPKs) and its upstream protein kinase in human gastric cancer and to evaluate the relationship between protein levels and clinicopathological parameters.
  • METHODS: Western blot was used to measure the expression of extracellular signal-regulated kinase (ERK)-1, ERK-2, ERK-3, p38 and mitogen or ERK activated protein kinaseMEK-1 proteins in surgically resected gastric carcinoma, adjacent normal mucosa and metastatic lymph nodes from 42 patients.
  • RESULTS: Compared with normal tissues, the protein levels of ERK-1 (integral optical density value 159 526+/-65 760 vs 122 807+/-65 515, P = 0.001), ERK-2 (168 471+/-95 051 vs 120 469+/-72 874, P<0.001), ERK-3 (118 651+/-71 513 vs 70 934+/-68 058, P<0.001), P38 (104 776+/-51 650 vs 82 930+/-40 392, P = 0.048) and MEK-1 (116 486+/-45 725 vs 101 434+/-49 387, P = 0.027) were increased in gastric cancer tissues.
  • In poorly differentiated cancers (n = 33), the protein levels of ERK-1 and ERK-2 in stage III and IV tumors were higher than those in stage I and II tumors (2.64+/-3.01 vs 1.01+/-0.33, P = 0.022; 2.05+/-1.54 vs 1.24+/-0.40, P = 0.030).
  • Gastric cancer tissues with either lymph node involvement (2.49+/-2.91 vs 1.03+/-0.36, P = 0.023; 1.98+/-1.49 vs 1.24+/-0.44, P = 0.036) or serosa invasion (2.39+/-2.82 vs 1.01+/-0.35, P = 0.022; 1.95+/-1.44 vs 1.14+/-0.36, P = 0.015) expressed higher protein levels of ERK-1 and ERK-2.
  • The expression of MEK-1 in gastric cancer cells metastasized to lymph nodes was higher than that of the primary site.
  • MEK-1 is also overexpressed in gastric cancer, particularly in metastatic lymph nodes.
  • Upregulation of MAPK signal transduction pathways may play an important role in tumorigenesis and metastatic potential of gastric cancer.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15655810.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 6; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; EC 2.7.12.2 / MAP Kinase Kinase 1
  • [Other-IDs] NLM/ PMC4250727
  •  go-up   go-down


47. Widder J, Kastenberger R, Fercher E, Schmid R, Langendijk JA, Dobrowsky W, Pötter R: Radiation dose associated with local control in advanced anal cancer: retrospective analysis of 129 patients. Radiother Oncol; 2008 Jun;87(3):367-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation dose associated with local control in advanced anal cancer: retrospective analysis of 129 patients.
  • BACKGROUND AND PURPOSE: To retrospectively analyse a large consecutive cohort of patients with anal cancer for treatment-related factors influencing local control and survival.
  • MATERIALS AND METHODS: All patients referred for primary radiotherapy at Medical University of Vienna in 1990-2002 with anal canal carcinoma without distant metastases were analysed.
  • RESULTS: Median age was 67 years (n=129), the UICC stage distribution was 15%, 58%, and 27% for stages I, II, and III, respectively.
  • Stage and age were significant factors for overall and colostomy-free-survival, N-stage for disease-free-survival.
  • Shorter overall treatment time favoured local control in stage T1-2 (p=.015), higher total radiation dose and female gender were associated with improved local control in T3-4 tumours (p=.021).
  • CONCLUSIONS: These results support potential improvement of anal cancer treatment by studying advanced technology such as IMRT, making it possible to tailor high-dose regions.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18501453.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


48. Alvarez G, Perry A, Tan BR, Wang HL: Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification. Mod Pathol; 2006 Jul;19(7):942-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification.
  • The EGFR status in squamous cell carcinoma of the anal canal, an uncommon malignancy traditionally treated with chemoradiation, has not been well investigated.
  • In this study, 38 primary squamous cell carcinomas of the anal canal were immunohistochemically examined for EGFR expression and analyzed by fluorescence in situ hybridization (FISH) for EGFR gene copy numbers.
  • There were no significant differences among tumors stratified by stage, degree of keratinization, or tissue block storage times.
  • These results demonstrate that EGFR is overexpressed in more than one-half of the squamous cell carcinomas of the anal canal through mechanisms other than gene amplification.
  • [MeSH-major] Anus Neoplasms / metabolism. Carcinoma, Squamous Cell / metabolism. Receptor, Epidermal Growth Factor / metabolism. Up-Regulation
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Gene Amplification. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16648870.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


49. Pawlik TM, Hawke DH, Liu Y, Krishnamurthy S, Fritsche H, Hunt KK, Kuerer HM: Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein. BMC Cancer; 2006;6:68
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein.
  • We sought to determine whether ICAT technology could quantify and identify differential expression of tumor-specific proteins in nipple aspirate fluid (NAF) from the tumor-bearing and contralateral disease-free breasts of patients with unilateral early-stage breast cancer.
  • METHODS: Paired NAF samples from 18 women with stage I or II unilateral invasive breast carcinoma and 4 healthy volunteers were analyzed using ICAT labeling, sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE), liquid chromatography, and MS.
  • Western blot analysis of NAF from an independent sample set from 12 women (8 with early-stage breast cancer and 4 healthy volunteers) was also performed.
  • Western blot analysis of pooled samples of NAF from healthy volunteers versus NAF from women with breast cancer confirmed the overexpression of vitamin D-binding protein in tumor-bearing breasts.
  • Proteomic screening techniques using ICAT and NAF may be used to find markers for diagnosis of breast cancer.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / diagnosis. Mass Spectrometry / methods. Nipples / secretion. Proteomics / methods. Vitamin D-Binding Protein / metabolism
  • [MeSH-minor] Blotting, Western. Body Fluids / metabolism. Carbon Isotopes. Carcinoma / diagnosis. Carcinoma / metabolism. Chromatography, Liquid. Female. Humans. Middle Aged. Peptides / analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proteomics. 2003 Oct;3(10):1863-73 [14625848.001]
  • [Cites] Mol Cell Proteomics. 2003 Nov;2(11):1198-204 [14506205.001]
  • [Cites] Bioconjug Chem. 2004 Mar-Apr;15(2):380-8 [15025535.001]
  • [Cites] J Biol Chem. 2004 Apr 2;279(14):14129-39 [14729674.001]
  • [Cites] J Biol Chem. 2004 May 7;279(19):20127-36 [14988394.001]
  • [Cites] Biochem Soc Trans. 2004 Jun;32(Pt3):520-3 [15157176.001]
  • [Cites] J Proteome Res. 2004 May-Jun;3(3):604-12 [15253443.001]
  • [Cites] Genome Biol. 2004;5(8):R54 [15287976.001]
  • [Cites] World J Gastroenterol. 2004 Sep 15;10(18):2652-6 [15309713.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6402-9 [15374947.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Oct;130(10):615-22 [15243804.001]
  • [Cites] Mol Cell Proteomics. 2004 Oct;3(10):960-9 [15238602.001]
  • [Cites] J Natl Cancer Inst. 1977 Oct;59(4):1073-80 [903989.001]
  • [Cites] Lancet. 1979 Dec 22-29;2(8156-8157):1335-6 [92676.001]
  • [Cites] Cancer Res. 1980 Dec;40(12):4764-7 [6254651.001]
  • [Cites] Biochem Biophys Res Commun. 1981 Aug 31;101(4):1131-8 [6272774.001]
  • [Cites] Cancer Res. 1981 Dec;41(12 Pt 1):5121-4 [6272989.001]
  • [Cites] Cancer Res. 1984 Apr;44(4):1677-81 [6322984.001]
  • [Cites] Nat Biotechnol. 1999 Jul;17(7):676-82 [10404161.001]
  • [Cites] Nat Biotechnol. 1999 Oct;17(10):994-9 [10504701.001]
  • [Cites] FEBS J. 2005 Jan;272(1):2-15 [15634327.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Feb 5;815(1-2):215-25 [15652811.001]
  • [Cites] Breast Cancer Res Treat. 2005 Jan;89(2):149-57 [15692757.001]
  • [Cites] Int J Cancer. 2005 May 1;114(5):791-6 [15609313.001]
  • [Cites] Mol Biotechnol. 2005 Mar;29(3):233-44 [15767701.001]
  • [Cites] Proteomics. 2005 May;5(7):1797-805 [15825149.001]
  • [Cites] Nat Genet. 2003 Mar;33(3):349-55 [12590263.001]
  • [Cites] N Engl J Med. 1992 Jul 30;327(5):319-28 [1620171.001]
  • [Cites] Breast Cancer Res Treat. 1994;31(2-3):357-70 [7881112.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Dec;5(12):967-70 [8959318.001]
  • [Cites] Anal Chem. 1997 Apr 15;69(8):1518-24 [9109352.001]
  • [Cites] Br J Cancer. 1997;76(4):494-501 [9275027.001]
  • [Cites] N Engl J Med. 1998 Apr 16;338(16):1089-96 [9545356.001]
  • [Cites] Lancet. 2000 Aug 12;356(9229):567 [10950239.001]
  • [Cites] Curr Opin Biotechnol. 2000 Aug;11(4):413-8 [10975463.001]
  • [Cites] Curr Opin Chem Biol. 2000 Oct;4(5):489-94 [11006534.001]
  • [Cites] Ann N Y Acad Sci. 2000;923:312-5 [11193768.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1462-7 [11230492.001]
  • [Cites] Breast Cancer Res. 2000;2(2):92-9 [11250698.001]
  • [Cites] Anal Chem. 2001 Mar 1;73(5):978-86 [11289445.001]
  • [Cites] EMBO J. 2001 Sep 3;20(17):4782-93 [11532942.001]
  • [Cites] Nat Biotechnol. 2001 Oct;19(10):946-51 [11581660.001]
  • [Cites] J Am Soc Mass Spectrom. 2001 Dec;12(12):1238-46 [11766750.001]
  • [Cites] Dis Markers. 2001;17(4):301-7 [11790897.001]
  • [Cites] J Mass Spectrom. 2002 Jan;37(1):1-14 [11813306.001]
  • [Cites] Breast J. 2001 Nov-Dec;7(6):378-87 [11843848.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Nat Biotechnol. 2002 May;20(5):512-5 [11981568.001]
  • [Cites] Biochemistry. 2002 May 28;41(21):6714-22 [12022875.001]
  • [Cites] EMBO J. 2002 Oct 1;21(19):5088-96 [12356725.001]
  • [Cites] Curr Opin Chem Biol. 2002 Oct;6(5):666-75 [12413552.001]
  • [Cites] Cancer. 2002 Dec 1;95(11):2276-82 [12436432.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6740-9 [12438275.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):749-54 [12576445.001]
  • [Cites] Anal Chem. 2003 May 1;75(9):2159-65 [12720356.001]
  • [Cites] Breast Cancer Res. 2003;5(4):R82-7 [12817998.001]
  • [Cites] J Am Soc Mass Spectrom. 2003 Jul;14(7):696-703 [12837591.001]
  • [Cites] Breast Cancer Res. 2003;5(6):320-8 [14580250.001]
  • [Cites] Int J Biol Markers. 2003 Oct-Dec;18(4):241-72 [14756541.001]
  • (PMID = 16542425.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carbon Isotopes; 0 / Peptides; 0 / Vitamin D-Binding Protein
  • [Other-IDs] NLM/ PMC1431555
  •  go-up   go-down


50. Lorentzen A, Vogel LK, Lewinsky RH, Saebø M, Skjelbred CF, Godiksen S, Hoff G, Tveit KM, Lothe IM, Ikdahl T, Kure EH, Mitchelmore C: Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma. BMC Cancer; 2007 Oct 12;7:192
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma.
  • BACKGROUND: It has recently been shown that NDRG2 mRNA is down-regulated or undetectable in several human cancers and cancer cell-lines.
  • The aim of this study has been to examine NDRG2 mRNA expression in colon cancer.
  • When comparing adenomas/carcinomas with adjacent normal tissue from the same individual, NDRG2 expression levels were significantly reduced in both high-risk adenoma (p < 0.001) and in colorectal carcinoma (p < 0.001).
  • There was a trend for NDRG2 levels to decrease with increasing Dukes' stage (p < 0.05).
  • CONCLUSION: Our results demonstrate that expression of NDRG2 is down-regulated at a late stage during colorectal carcinogenesis.
  • Future studies are needed to address whether NDRG2 down-regulation is a cause or consequence of the progression of colorectal adenomas to carcinoma.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1999 May 13;18(19):3004-16 [10378696.001]
  • [Cites] J Mol Diagn. 2006 May;8(2):193-201 [16645205.001]
  • [Cites] Anal Biochem. 2000 Feb 15;278(2):175-84 [10660460.001]
  • [Cites] Proteins. 2002 May 1;47(2):163-8 [11933063.001]
  • [Cites] Mol Cell Biochem. 2002 Jan;229(1-2):35-44 [11936845.001]
  • [Cites] Scand J Gastroenterol. 2003 Jun;38(6):635-42 [12825872.001]
  • [Cites] Int J Cancer. 2003 Sep 1;106(3):342-7 [12845671.001]
  • [Cites] FEBS Lett. 2003 Oct 23;553(3):413-8 [14572661.001]
  • [Cites] Neurobiol Dis. 2004 Jun;16(1):48-58 [15207261.001]
  • [Cites] Mech Dev. 1999 May;83(1-2):39-52 [10381566.001]
  • [Cites] World J Gastroenterol. 2004 Dec 1;10(23):3518-21 [15526377.001]
  • [Cites] Biochem Soc Trans. 2005 Aug;33(Pt 4):672-5 [16042571.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7121-6 [16103061.001]
  • [Cites] Oncogene. 2006 Jan 5;25(1):111-21 [16247483.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] J Biol Chem. 2006 Dec 22;281(51):39159-68 [17050536.001]
  • (PMID = 17935612.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / NDRG2 protein, human; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC2099434
  •  go-up   go-down


51. Rogers LJ, Howard B, Van Wijk L, Wei W, Dehaeck K, Soeters R, Denny LA: Chemoradiation in advanced vulval carcinoma. Int J Gynecol Cancer; 2009 May;19(4):745-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoradiation in advanced vulval carcinoma.
  • INTRODUCTION: Vulval carcinoma is uncommon, affecting approximately 2 per 100,000 women annually.
  • Advanced vulval carcinomas involve midline structures (such as clitoris, urethra, or anus) and/or adjacent pelvic organs or bone, and adequate excision may require urinary diversion, colostomy, or pelvic exenteration.
  • Less morbid and less mutilating therapeutic alternatives have been investigated, particularly chemoradiation, which has shown success in the management of anal carcinomas.
  • This is a retrospective study of the GSH's experience of the use of chemoradiation as primary therapy for women with advanced vulval carcinoma.
  • Other prognostic factors for survival were performance status and tumor stage.
  • Performance status, age, and tumor stage were also associated with survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Vulvar Neoplasms / drug therapy. Vulvar Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19509582.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


52. Mosthaf FA, Hanhoff NJ, Goetzenich A, Wolf E, Knechten H: [High incidence of non-AIDS-defined cancers among HIV-infected patients in Germany. A 3-year nationwide review]. Dtsch Med Wochenschr; 2006 Aug 25;131(34-35):1849-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The data were collected on all AIDS- and not-AIDS-defined haematological malignancies and all AIDS- and not-AIDS-defined solid malignant tumors in HIV-positive patients, as well as on time of diagnosis of the malignancy, tumor stage, tumor treatment and response to treatment.
  • 180 malignant neoplasms (47%) were AIDS-defined: 89 Kaposi's sarcomas, 82 aggressive B-cell lymphomas and 9 invasive cervical carcinomas.
  • The aggressive B-cell lymphomas consisted of 19 cases of Burkitt's lymphoma, 8 of Castleman's disease and 12 of primary cerebral malignant lymphoma.
  • Of the 200 (52.6%) not-AIDS-defined malignant tumors 133 were 133 solid tumors, 40 of them anal carcinoma (20% of all not-AIDS-defined malignancies) and 67 haematological malignancies, 22 of these Hodgkin's lymphoma (11.0% of all not-AIDS-defined malignancies).
  • The incidence of anal carcinoma is estimated to be 34 (95% CI 24-470) per 100 000 patient-years, that of Hodgkin's lymphoma 19 (95% CI 12-28) per 100 000 patient-years.
  • Of special note is the high incidence of anal carcinoma and Hodgkin's lymphoma, compared with their incidence among the entire German population.
  • [MeSH-major] Anus Neoplasms / epidemiology. HIV Infections / complications. Hodgkin Disease / epidemiology. Neoplasms / epidemiology. Neoplasms / virology
  • [MeSH-minor] Carcinoma / epidemiology. Female. Germany / epidemiology. Humans. Incidence. Male. Retrospective Studies. Sex Factors. Surveys and Questionnaires


53. Dietz DW, Dehdashti F, Grigsby PW, Malyapa RS, Myerson RJ, Picus J, Ritter J, Lewis JS, Welch MJ, Siegel BA: Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum; 2008 Nov;51(11):1641-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study.
  • METHODS: Patients with locally invasive (T2-4) primary or node-positive rectal cancer located <12 cm from the anal verge were recruited for this pilot study.
  • Pretreatment tumor size and stage were determined by endorectal ultrasonography, CT, and magnetic resonance imaging.
  • CONCLUSIONS: The results of this small pilot study suggest that (60)Cu-ATSM-PET may be predictive of survival and, possibly, tumor response to neoadjuvant chemoradiotherapy in patients with rectal cancer.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / therapy. Organometallic Compounds. Positron-Emission Tomography. Rectal Neoplasms / diagnosis. Rectal Neoplasms / therapy. Thiosemicarbazones
  • [MeSH-minor] Adult. Aged. Cell Hypoxia. Cohort Studies. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Pilot Projects. Predictive Value of Tests. Prognosis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18682881.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R24 CA086307
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organometallic Compounds; 0 / Thiosemicarbazones; 0 / copper (II) diacetyl-di(N(4)-methylthiosemicarbazone)
  • [Other-IDs] NLM/ NIHMS802312; NLM/ PMC4962601
  •  go-up   go-down


54. Chen YW, Yen SH, Chen SY, Huang PI, Shiau CY, Liu YM, Lin JK, Wang LW: Anus-preservation treatment for anal cancer: retrospective analysis at a single institution. J Surg Oncol; 2007 Oct 1;96(5):374-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anus-preservation treatment for anal cancer: retrospective analysis at a single institution.
  • BACKGROUND: To evaluate anus-preservation treatment for anal cancer.
  • METHODS: Review of 42 patients (24 M/18 F; median age, 70 years; range, 13-95) with stage I-IIIB disease (squamous cell carcinoma [SqCC], 33; adenocarcinoma, 9) who received curative radiotherapy between 1991 and 2004.
  • Five-year functional anus-preservation rate was 64%.
  • In multivariate analysis, OS was affected by performance status (P < 0.001), N stage (P = 0.009), and pathological type (P = 0.006).
  • Only N stage (P = 0.001) affected DFS.
  • CONCLUSION: With careful monitoring of toxicity, non-surgical anus-preservation treatment with good tumor control is feasible.
  • [MeSH-major] Adenocarcinoma / therapy. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 Wiley-Liss, Inc
  • (PMID = 17492635.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


55. Compérat E, Egevad L, Camparo P, Roupret M, Vaessen C, Valdman A, Jonmarker S, Capron F, Cussenot O, Charlotte F: Clinical significance of intratumoral CD8+ regulatory T cells in prostate carcinoma. Anal Quant Cytol Histol; 2010 Feb;32(1):39-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of intratumoral CD8+ regulatory T cells in prostate carcinoma.
  • OBJECTIVE: To explore Foxp3, a member of the forkhead box family of transcription factors, which is a major gene for regulatory T (Treg) cell development of CD4+CD25+ or CD8+CD25+ phenotype.
  • Serum prostate-specific antigen levels before and after RP, Gleason score (GS), surgical margin status and pathologic stage were available.
  • CONCLUSION: Treg cells were more common in cancer than in benign prostatic tissue.
  • Patients with prostate cancer show an immunosuppressive regulatory profile, including nonresponsive Tregs.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20701086.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


56. Courter LA, Luch A, Musafia-Jeknic T, Arlt VM, Fischer K, Bildfell R, Pereira C, Phillips DH, Poirier MC, Baird WM: The influence of diesel exhaust on polycyclic aromatic hydrocarbon-induced DNA damage, gene expression, and tumor initiation in Sencar mice in vivo. Cancer Lett; 2008 Jun 28;265(1):135-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated the influence of diesel exhaust particulate matter on PAH-induced cytochrome P450 (CYP) activity, PAH-DNA adduct formation, expression of certain candidate genes and the frequency of tumor initiation in the two-stage Sencar mouse model.
  • The applied diesel particulate matter (SRM(1975)) altered the tumor initiating potency of DBP: a statistically significant decrease in overall tumor and carcinoma burden was observed following 25 weeks of promotion with 12-O-tetradecanoylphorbol-13-acetate (TPA), compared with DBP exposure alone.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • Hazardous Substances Data Bank. DIBENZO(A,L)PYRENE .
  • Hazardous Substances Data Bank. Benzo(a)pyrene .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 1995 Sep;16(9):2083-9 [7554058.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):2979-84 [8674051.001]
  • [Cites] Science. 1996 Oct 18;274(5286):430-2 [8832894.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jun 29;358(2):442-8 [17490615.001]
  • [Cites] Mutat Res. 2007 Dec 1;625(1-2):72-82 [17612574.001]
  • [Cites] Nat Protoc. 2007;2(11):2772-81 [18007613.001]
  • [Cites] Chem Res Toxicol. 2007 Dec;20(12):1797-810 [17944540.001]
  • [Cites] Carcinogenesis. 2000 Apr;21(4):653-61 [10753200.001]
  • [Cites] N Engl J Med. 2000 Dec 14;343(24):1742-9 [11114312.001]
  • [Cites] Hum Exp Toxicol. 2000 Oct;19(10):573-95 [11211997.001]
  • [Cites] Environ Health Perspect. 2001 Jan;109(1):71-4 [11171528.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2727-31 [11289154.001]
  • [Cites] Carcinogenesis. 2001 Jul;22(7):1077-86 [11408352.001]
  • [Cites] Histol Histopathol. 2001 Jul;16(3):861-8 [11510978.001]
  • [Cites] Int J Cancer. 2001 Oct 1;94(1):121-7 [11668486.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] JAMA. 2002 Mar 6;287(9):1132-41 [11879110.001]
  • [Cites] Mutat Res. 2002 Mar 25;515(1-2):85-98 [11909757.001]
  • [Cites] Chemosphere. 2002 Apr;47(1):57-64 [11996136.001]
  • [Cites] Toxicol Sci. 2002 Jun;67(2):241-6 [12011483.001]
  • [Cites] Biochim Biophys Acta. 2002 Sep 19;1572(2-3):285-93 [12223276.001]
  • [Cites] Chem Res Toxicol. 2002 Sep;15(9):1127-35 [12230405.001]
  • [Cites] Carcinogenesis. 2002 Nov;23(11):1937-45 [12419844.001]
  • [Cites] Environ Res. 2003 Jul;92(3):191-6 [12804515.001]
  • [Cites] Cancer Sci. 2004 Jan;95(1):1-6 [14720319.001]
  • [Cites] Glycoconj J. 2004;19(7-9):557-63 [14758080.001]
  • [Cites] Toxicol In Vitro. 2004 Jun;18(3):377-91 [15046786.001]
  • [Cites] Environ Mol Mutagen. 2004;44(2):99-107 [15278913.001]
  • [Cites] J Invest Dermatol. 1974 Oct;63(4):343-9 [4424714.001]
  • [Cites] Int J Environ Anal Chem. 1981;9(2):93-144 [7012053.001]
  • [Cites] Carcinogenesis. 1982;3(4):371-5 [6284398.001]
  • [Cites] Cancer Lett. 1984 Oct;24(3):327-33 [6437667.001]
  • [Cites] Mol Pharmacol. 1997 Dec;52(6):974-82 [9415707.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2070-5 [9605744.001]
  • [Cites] Chem Res Toxicol. 1998 Jun;11(6):686-95 [9625737.001]
  • [Cites] J Investig Dermatol Symp Proc. 1996 Apr;1(2):151-6 [9627710.001]
  • [Cites] Mutat Res. 1999 Mar 8;424(1-2):155-66 [10064858.001]
  • [Cites] Mutagenesis. 1999 May;14(3):301-15 [10374998.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Dec 1;201(2):178-85 [15541757.001]
  • [Cites] Chem Res Toxicol. 2004 Dec;17(12):1667-74 [15606143.001]
  • [Cites] Chem Res Toxicol. 2005 Feb;18(2):224-31 [15720126.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1251-8 [15735009.001]
  • [Cites] Crit Rev Toxicol. 2005 Jun;35(5):379-411 [16097136.001]
  • [Cites] Curr Dir Autoimmun. 2006;9:1-17 [16394652.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):845-53 [16467098.001]
  • [Cites] Chem Res Toxicol. 2006 Feb;19(2):288-94 [16485905.001]
  • [Cites] Toxicol Lett. 2006 Aug 20;165(2):182-94 [16713138.001]
  • [Cites] BMC Genomics. 2006;7:260 [17042939.001]
  • [Cites] Ann N Y Acad Sci. 2006 Sep;1076:253-65 [17119207.001]
  • [Cites] Toxicol Sci. 2007 Jan;95(1):63-73 [17060372.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2007;47:263-92 [16970545.001]
  • [Cites] Mutat Res. 2007 Feb 3;615(1-2):87-97 [17141280.001]
  • [Cites] Int J Cancer. 2007 Mar 15;120(6):1161-8 [17187366.001]
  • [Cites] Toxicology. 2007 Mar 7;231(2-3):159-74 [17240030.001]
  • [Cites] Chem Res Toxicol. 2007 Mar;20(3):489-96 [17291012.001]
  • [Cites] Cancer Res. 1987 Jul 15;47(14):3701-6 [3109730.001]
  • [Cites] Sci Total Environ. 1987 Oct;66:95-114 [3317821.001]
  • [Cites] Chem Biol Interact. 1988;68(1-2):127-36 [3203403.001]
  • [Cites] Toxicology. 1990 Jan-Feb;60(1-2):127-35 [1690463.001]
  • [Cites] Carcinogenesis. 1990 Sep;11(9):1611-9 [2401051.001]
  • [Cites] Endocrinology. 1991 Aug;129(2):970-82 [1649753.001]
  • [Cites] Carcinogenesis. 1991 Oct;12(10):1939-44 [1934274.001]
  • [Cites] Carcinogenesis. 1992 Jul;13(7):1053-74 [1638670.001]
  • [Cites] Carcinogenesis. 1993 May;14(5):875-8 [8504480.001]
  • [Cites] N Engl J Med. 1993 Dec 9;329(24):1753-9 [8179653.001]
  • [Cites] Environ Health Perspect. 1993 Dec;101 Suppl 4:155-65 [7515806.001]
  • [Cites] Mol Carcinog. 1994 Jul;10(3):159-68 [8043197.001]
  • (PMID = 18353537.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES00210; United States / NCI NIH HHS / CA / R01 CA028825-21; United States / NCI NIH HHS / CA / R01 CA028825-19; United States / NCI NIH HHS / CA / CA028825-21; United States / NCI NIH HHS / CA / R01 CA028825; United States / NCI NIH HHS / CA / CA028825-19; United Kingdom / Cancer Research UK / / ; United States / NCI NIH HHS / CA / R01 CA028825-23; United States / NCI NIH HHS / CA / CA028825-22; United States / NCI NIH HHS / CA / CA28825; United States / NCI NIH HHS / CA / CA028825-20; United States / NCI NIH HHS / CA / R01 CA028825-20; United States / NCI NIH HHS / CA / CA028825-24; United States / NCI NIH HHS / CA / R01 CA028825-22; United States / NIEHS NIH HHS / ES / T32 ES007060; United States / NCI NIH HHS / CA / R01 CA028825-24; United States / NIEHS NIH HHS / ES / P30 ES000210; United States / NCI NIH HHS / CA / CA028825-23
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Benzopyrenes; 0 / Carcinogens; 0 / DNA Adducts; 0 / Particulate Matter; 0 / Polycyclic Hydrocarbons, Aromatic; 0 / Vehicle Emissions; 0 / polycyclic aromatic hydrocarbons-DNA adduct; 191-30-0 / dibenzo(a,l)pyrene; 3417WMA06D / Benzo(a)pyrene; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / Cyp1b1 protein, mouse; EC 1.14.14.1 / Cytochrome P-450 CYP1A1; EC 1.14.14.1 / Cytochrome P-450 CYP1B1; NI40JAQ945 / Tetradecanoylphorbol Acetate
  • [Other-IDs] NLM/ NIHMS53855; NLM/ PMC2519885
  •  go-up   go-down


57. Kommoss S, Schmidt D, Kommoss F, Hedderich J, Harter P, Pfisterer J, du Bois A: Histological grading in a large series of advanced stage ovarian carcinomas by three widely used grading systems: consistent lack of prognostic significance. A translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol). Virchows Arch; 2009 Mar;454(3):249-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological grading in a large series of advanced stage ovarian carcinomas by three widely used grading systems: consistent lack of prognostic significance. A translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol).
  • While there is no doubt that histologic grading is applicable in early stage ovarian carcinoma, it is still in controversial discussion concerning advanced stage ovarian carcinoma.
  • It was the aim of this study to assess the three most widely used grading systems for ovarian carcinoma in terms of prognostic significance, concordance rates, and reproducibility in a large number of advanced stage ovarian carcinomas of all types after standardized chemotherapy.
  • Representative hematoxylin and eosin slides from 334 cases of stage IIB-IV ovarian carcinoma (prospective randomized, multi-center, phase III study) were used.
  • Grading of advanced stage ovarian carcinomas was of no value for estimation of prognosis in this homogeneously treated patient group.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2008 Feb;52(3):393-5 [18081817.001]
  • [Cites] Cancer. 1980 Feb;45(3):572-81 [7353206.001]
  • [Cites] Obstet Gynecol. 1982 May;59(5):576-82 [7070728.001]
  • [Cites] APMIS. 1991 Apr;99(4):353-8 [2036219.001]
  • [Cites] Gynecol Oncol. 1984 Jan;17(1):117-23 [6693048.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Am J Surg Pathol. 2007 Aug;31(8):1168-74 [17667538.001]
  • [Cites] Gynecol Oncol. 2003 Jun;89(3):447-52 [12798710.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Cancer. 1998 Mar 1;82(5):893-901 [9486579.001]
  • [Cites] Anal Quant Cytol Histol. 1986 Dec;8(4):354-7 [3814303.001]
  • [Cites] Histopathology. 2000 May;36(5):433-8 [10792484.001]
  • [Cites] Lancet. 2001 Jan 20;357(9251):176-82 [11213094.001]
  • [Cites] Int J Gynecol Pathol. 2000 Oct;19(4):348-53 [11109164.001]
  • [Cites] Gynecol Oncol. 2006 Oct;103(1):67-71 [16516280.001]
  • [Cites] Acta Obstet Gynecol Scand. 1971;50(1):1-7 [5558593.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Biometrics. 1977 Mar;33(1):159-74 [843571.001]
  • [Cites] Int J Gynecol Pathol. 1988;7(3):197-211 [2846458.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 3;95(17):1320-9 [12953086.001]
  • [Cites] Int J Gynecol Pathol. 2008 Apr;27(2):175-81 [18317226.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):496-504 [15087669.001]
  • [Cites] Int J Gynecol Pathol. 2003 Jan;22(1):52-6 [12496698.001]
  • [Cites] Int J Gynecol Pathol. 1989;8(2):147-55 [2714932.001]
  • [Cites] Int J Gynecol Pathol. 2000 Jan;19(1):7-15 [10638449.001]
  • [Cites] J Obstet Gynaecol Res. 2001 Dec;27(6):313-8 [11794816.001]
  • (PMID = 19172293.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  •  go-up   go-down


58. Hegele A, Hofmann R, Kosche B, Kropf J: Evaluation of cellular fibronectin plasma levels as a useful staging tool in different stages of transitional cell carcinoma of the bladder and renal cell carcinoma. Biomark Insights; 2007 Feb 07;2:1-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of cellular fibronectin plasma levels as a useful staging tool in different stages of transitional cell carcinoma of the bladder and renal cell carcinoma.
  • Reliable markers for both renal cell carcinoma (RCC) and transitional cell carcinoma of the bladder (TCC) are lacking.During tumor progression and invasion components of extracellular matrix (ECM) are degraded and parts of these different components are detectable in plasma.
  • Similar results were found in RCC with significant elevated cFN levels in metastatic RCC (p < 0.005) compared to localized stage of disease.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biomarkers. 2005 Jul-Aug;10(4):258-94 [16191485.001]
  • [Cites] J Urol. 2005 Nov;174(5):1771-5; discussion 1775-6 [16217281.001]
  • [Cites] Cancer. 2005 Jul 1;104(1):30-5 [15912517.001]
  • [Cites] Lancet Oncol. 2005 Sep;6(9):678-86 [16129368.001]
  • [Cites] Br J Cancer. 1997;76(6):777-83 [9310245.001]
  • [Cites] Eur Urol. 1997;31(1):40-8 [9032533.001]
  • [Cites] Int J Cancer. 1996 Nov 4;68(3):364-71 [8903479.001]
  • [Cites] Exp Cell Res. 1995 Nov;221(1):83-91 [7589259.001]
  • [Cites] Cancer Metastasis Rev. 1995 Sep;14(3):173-89 [8548867.001]
  • [Cites] J Hepatol. 1995;22(2 Suppl):77-81 [7665854.001]
  • [Cites] Br J Cancer. 1995 Mar;71(3):578-82 [7880741.001]
  • [Cites] Clin Chem. 1995 Sep;41(9):1283-7 [7656438.001]
  • [Cites] J Urol. 1993 Feb;149(2):268-71 [8426398.001]
  • [Cites] Jpn J Cancer Res. 1992 Dec;83(12):1327-33 [1483947.001]
  • [Cites] Urol Clin North Am. 1992 Aug;19(3):429-33 [1636228.001]
  • [Cites] Anal Biochem. 1991 Aug 15;197(1):258-65 [1952074.001]
  • [Cites] J Cell Biol. 1986 Nov;103(5):1671-7 [3023390.001]
  • [Cites] Arch Dermatol. 1988 Feb;124(2):221-5 [3341802.001]
  • [Cites] J Cell Biol. 1982 Nov;95(2 Pt 1):369-77 [6128348.001]
  • [Cites] Tumour Biol. 2004 May-Jun;25(3):111-6 [15361707.001]
  • [Cites] J Urol. 2004 Oct;172(4 Pt 1):1496-500 [15371878.001]
  • [Cites] Urol Res. 2003 Feb;30(6):363-6 [12599015.001]
  • [Cites] Mod Pathol. 2002 Aug;15(8):826-30 [12181267.001]
  • [Cites] Urol Res. 2002 May;30(2):126-9 [12086018.001]
  • [Cites] Eur Urol. 2001 Mar;39(3):292-9 [11275722.001]
  • [Cites] Int J Cancer. 2002 Apr 20;98(6):889-94 [11948468.001]
  • [Cites] Thromb Res. 2002 Jan 1;105(1):37-41 [11864705.001]
  • [Cites] J Urol. 2002 Jan;167(1):80-3 [11743280.001]
  • [Cites] Curr Probl Cancer. 2001 Jul-Aug;25(4):219-78 [11514784.001]
  • [Cites] J Urol. 2001 Aug;166(2):470-5 [11458049.001]
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3585-94 [10999749.001]
  • [Cites] Urol Int. 2000;64(4):198-201 [10895085.001]
  • [Cites] Cancer Lett. 2000 Jul 31;155(2):199-205 [10822136.001]
  • [Cites] J Urol. 2000 Feb;163(2):408-17 [10647643.001]
  • [Cites] Clin Chim Acta. 2006 Oct;372(1-2):83-93 [16730689.001]
  • [Cites] J Thromb Haemost. 2006 Jul;4(7):1461-9 [16839338.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2006 Jun;26(6):1193-5 [16709950.001]
  • [Cites] Curr Pharm Des. 2005;11(7):881-91 [15777241.001]
  • (PMID = 19662188.001).
  • [Journal-full-title] Biomarker insights
  • [ISO-abbreviation] Biomark Insights
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2717843
  • [Keywords] NOTNLM ; Biological markers / Extracellular matrix / Invasion / TRFIA / tumor progression
  •  go-up   go-down


59. Schütz A, Härtig W, Wobus M, Grosche J, Wittekind Ch, Aust G: Expression of ADAM15 in lung carcinomas. Virchows Arch; 2005 Apr;446(4):421-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to analyze the expression of ADAM15 and its potential ligand, integrin alpha(v)beta3 (CD51/CD61), in lung carcinoma cell lines and tissues.
  • Most small cell lung carcinomas (SCLCs) and non-SCLC cell lines were ADAM15, alpha(v) and beta3 integrin mRNA positive.
  • Half of the cell lines expressed ADAM15, and three expressed the alpha(v)beta3 heterodimer at the cell surface as shown using flow cytometry.
  • Paraffin sections of pulmonary epithelial tumors, including SCLCs (n=26), squamous cell cancer (SCCs, n=27) and adenocarcinomas (ACs, n=17) were stained with antibodies to the ectosolic and cytosolic domain of ADAM15 and alpha(v)beta3 integrin complex.
  • Overall analysis of all tumor specimens and each tumor type revealed no significant correlation between tumor stage or degree of differentiation and ADAM15 ectosolic or cytosolic domain expression in tumor cells.
  • In summary, lung carcinoma cell lines and tissues were frequently ADAM15 positive.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Squamous Cell / metabolism. Integrin alphaVbeta3 / metabolism. Lung Neoplasms / metabolism. Membrane Proteins / metabolism. Metalloendopeptidases / metabolism
  • [MeSH-minor] ADAM Proteins. Aged. Cell Line, Tumor. Female. Flow Cytometry. Humans. Lung / cytology. Lung / metabolism. Male. Middle Aged. Neoplasm Staging. RNA, Messenger / metabolism. RNA, Neoplasm / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1996 Aug;62(2):260-7 [8751559.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Jun 18;235(2):437-42 [9199213.001]
  • [Cites] Am J Pathol. 1999 Oct;155(4):1033-8 [10514384.001]
  • [Cites] J Cell Sci. 1999 Feb;112 ( Pt 4):579-87 [9914169.001]
  • [Cites] J Biol Chem. 2002 Sep 13;277(37):33683-9 [12091380.001]
  • [Cites] Differentiation. 1988;37(2):158-71 [2840315.001]
  • [Cites] Haematologica. 2002 Aug;87(8):836-45 [12161360.001]
  • [Cites] Curr Opin Cell Biol. 2003 Oct;15(5):598-606 [14519395.001]
  • [Cites] Pathol Res Pract. 1998;194(10):701-4 [9820866.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2062-9 [15026344.001]
  • [Cites] J Biol Chem. 1998 Oct 2;273(40):26236-47 [9748307.001]
  • [Cites] J Biol Chem. 2000 Nov 10;275(45):34922-30 [10944520.001]
  • [Cites] J Biol Chem. 1996 Mar 1;271(9):4593-6 [8617717.001]
  • [Cites] Thromb Haemost. 2003 Apr;89(4):622-31 [12669115.001]
  • [Cites] J Cell Biol. 1996 Sep;134(5):1323-32 [8794871.001]
  • [Cites] Cell. 1996 May 31;85(5):683-93 [8646777.001]
  • [Cites] Mol Cell Biol. 2003 Aug;23(16):5614-24 [12897135.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1986;409(2):127-47 [2424168.001]
  • [Cites] Mol Immunol. 1987 Jul;24(7):699-705 [3309626.001]
  • [Cites] Trends Cell Biol. 1994 Jul;4(7):256-61 [14731666.001]
  • [Cites] Eur Respir J. 1998 Feb;11(2):400-7 [9551745.001]
  • [Cites] Clin Exp Metastasis. 2002;19(8):717-25 [12553378.001]
  • [Cites] J Biol Chem. 2002 May 17;277(20):17804-10 [11882657.001]
  • [Cites] Neoplasia. 2002 May-Jun;4(3):191-4 [11988838.001]
  • [Cites] Oncol Res. 1993;5(10-11):441-51 [8054705.001]
  • [Cites] Pathobiology. 2004;71(4):185-92 [15263807.001]
  • [Cites] Biochem Soc Trans. 1999 Feb;27(2):255-9 [10093743.001]
  • [Cites] Anal Biochem. 1984 Feb;136(2):458-64 [6721145.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):1129-41 [11891209.001]
  • [Cites] Pathol Int. 1995 Jul;45(7):493-500 [7551009.001]
  • [Cites] J Cell Biol. 2004 Mar 15;164(6):935-41 [15024036.001]
  • [Cites] Arthritis Rheum. 1999 Sep;42(9):1946-50 [10513811.001]
  • [Cites] Arthritis Rheum. 2001 Sep;44(9):2046-54 [11592366.001]
  • [Cites] Hum Pathol. 1997 Sep;28(9):1018-25 [9308725.001]
  • [Cites] J Comp Neurol. 2003 Oct 6;465(1):1-10 [12926012.001]
  • [Cites] J Biol Chem. 1998 Mar 27;273(13):7345-50 [9516430.001]
  • [Cites] Int J Cancer. 1976 Jan 15;17(1):62-70 [175022.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1613-7 [11696421.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1209-14 [14973118.001]
  • [Cites] Am J Pathol. 1998 Nov;153(5):1347-51 [9811323.001]
  • [Cites] Cancer Res. 1997 Apr 15;57(8):1554-60 [9108459.001]
  • [Cites] Jpn J Cancer Res. 1996 May;87(5):451-8 [8641981.001]
  • [Cites] J Biol Chem. 2000 May 19;275(20):15490-7 [10809781.001]
  • [Cites] Genes Dev. 2003 Jan 1;17(1):7-30 [12514095.001]
  • [Cites] Exp Cell Res. 2001 Nov 15;271(1):152-60 [11697891.001]
  • [Cites] J Cell Biol. 1995 Oct;131(2):275-8 [7593158.001]
  • [Cites] J Exp Med. 1999 Jan 4;189(1):169-78 [9874573.001]
  • [Cites] FASEB J. 1997 Feb;11(2):173-80 [9039960.001]
  • [Cites] J Cancer Res Clin Oncol. 1980 Jan;96(1):27-33 [7358770.001]
  • (PMID = 15756594.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Integrin alphaVbeta3; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / ADAM15 protein, human; EC 3.4.24.- / Metalloendopeptidases
  •  go-up   go-down


60. Xi Z, LinLin M, Ye T: Human epididymis protein 4 is a biomarker for transitional cell carcinoma in the urinary system. J Clin Lab Anal; 2009;23(6):357-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human epididymis protein 4 is a biomarker for transitional cell carcinoma in the urinary system.
  • OBJECTIVE: To investigate human epididymis protein 4 (HE4) levels in transitional cell carcinoma (TCC) of the urinary system and its relationship with clinicopathological features.
  • There was no difference between HE4 levels based on tumor recurrence, clinical TNM stage, lymph node metastasis, or pathological stage (P>0.05).
  • CONCLUSIONS: HE4 may be a screening tool for early diagnosis of TCC in the urinary system, and may become a prognostic marker for TCC in the urinary system.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Transitional Cell / blood. Epididymal Secretory Proteins / metabolism. Urologic Neoplasms / blood

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19927341.001).
  • [ISSN] 1098-2825
  • [Journal-full-title] Journal of clinical laboratory analysis
  • [ISO-abbreviation] J. Clin. Lab. Anal.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DEFB126 protein, human; 0 / Epididymal Secretory Proteins; 0 / beta-Defensins
  •  go-up   go-down


61. Negroni MP, Fiszman GL, Azar ME, Morgado CC, Español AJ, Pelegrina LT, de la Torre E, Sales ME: Immunoglobulin G from breast cancer patients in stage I stimulates muscarinic acetylcholine receptors in MCF7 cells and induces proliferation. Participation of nitric oxide synthase-derived nitric oxide. J Clin Immunol; 2010 May;30(3):474-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoglobulin G from breast cancer patients in stage I stimulates muscarinic acetylcholine receptors in MCF7 cells and induces proliferation. Participation of nitric oxide synthase-derived nitric oxide.
  • In this work, we investigated the presence of autoantibodies against mAChR in the sera of breast cancer patients in stage I (T1N0Mx-IgG).
  • T1N0Mx-IgG promotes cell proliferation, mimicking the action of the muscarinic agonist carbachol.
  • DISCUSSION: IgG from patients with breast cancer in early stages could be promoting tumor progression by muscarinic activation, and its presence could be determining the prognosis of this illness.
  • [MeSH-major] Autoantibodies / pharmacology. Breast Neoplasms / immunology. Carcinoma / immunology. Immunoglobulin G / pharmacology. Nitric Oxide / metabolism
  • [MeSH-minor] Carbachol / pharmacology. Cell Line, Tumor. Cell Proliferation / drug effects. Cholinergic Agonists / pharmacology. Chromatography, Affinity. Disease Progression. Female. Humans. Neoplasm Staging. Nitric Oxide Synthase / metabolism. Receptor, Muscarinic M3 / immunology. Receptor, Muscarinic M4 / immunology. Signal Transduction / drug effects

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. CARBACHOL CHLORIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunity. 1998 Dec;9(6):757-63 [9881966.001]
  • [Cites] J Biol Chem. 2002 Sep 20;277(38):34666-73 [12089144.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6245-7 [10841527.001]
  • [Cites] Annu Rev Immunol. 1994;12:337-65 [8011285.001]
  • [Cites] Exp Cell Res. 1977 Feb;104(2):255-62 [65285.001]
  • [Cites] Zhonghua Nei Ke Za Zhi. 2008 Jul;47(7):563-5 [19035167.001]
  • [Cites] Curr Med Chem. 2005;12(24):2915-21 [16305479.001]
  • [Cites] Front Biosci. 2008 May 01;13:5257-78 [18508585.001]
  • [Cites] Int J Mol Med. 2004 Feb;13(2):311-7 [14719140.001]
  • [Cites] Braz J Med Biol Res. 2008 Sep;41(9):796-803 [18820770.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6459-62 [16818612.001]
  • [Cites] Immunol Lett. 2003 Dec 15;90(2-3):103-22 [14687712.001]
  • [Cites] Clin Immunol. 2004 Nov;113(2):193-202 [15451477.001]
  • [Cites] Pharmacology. 2000 Jul;61(1):37-42 [10895079.001]
  • [Cites] J Recept Signal Transduct Res. 2008;28(4):375-401 [18702010.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 May;13(5):530-42 [17448912.001]
  • [Cites] Eur J Gynaecol Oncol. 2001;22(4):249-56 [11695802.001]
  • [Cites] Int J Mol Med. 1999 Jun;3(6):633-7 [10341295.001]
  • [Cites] Cancer Detect Prev. 2005;29(1):59-65 [15734219.001]
  • [Cites] Int J Mol Med. 2002 Jun;9(6):651-7 [12011984.001]
  • [Cites] Life Sci. 2003 Mar 28;72(18-19):2173-82 [12628476.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Sep 9;334(4):1359-64 [16040004.001]
  • [Cites] Arch Neurol. 1999 Feb;56(2):172-7 [10025422.001]
  • [Cites] Am J Physiol Cell Physiol. 2009 Feb;296(2):C221-32 [19036940.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12659-64 [11606714.001]
  • [Cites] Cancer Lett. 2005 Dec 18;230(2):187-98 [16297705.001]
  • [Cites] Exp Clin Cardiol. 2005 Fall;10(3):170-2 [19641683.001]
  • [Cites] Prog Med Chem. 2005;43:105-36 [15850824.001]
  • [Cites] Trends Immunol. 2002 May;23(5):240-5 [12102744.001]
  • [Cites] J Clin Invest. 1990 Jan;85(1):264-73 [2404026.001]
  • [Cites] Int Immunopharmacol. 2006 Aug;6(8):1323-30 [16782546.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Br J Pharmacol. 2001 Nov;134(5):951-6 [11682442.001]
  • [Cites] Cancer Res. 2008 May 15;68(10):3573-8 [18483237.001]
  • [Cites] Semin Cancer Biol. 2008 Jun;18(3):211-7 [18262434.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4693-700 [18559515.001]
  • [Cites] Nat Clin Pract Rheumatol. 2008 Sep;4(9):491-8 [18756274.001]
  • (PMID = 20157846.001).
  • [ISSN] 1573-2592
  • [Journal-full-title] Journal of clinical immunology
  • [ISO-abbreviation] J. Clin. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Cholinergic Agonists; 0 / Immunoglobulin G; 0 / Receptor, Muscarinic M3; 0 / Receptor, Muscarinic M4; 31C4KY9ESH / Nitric Oxide; 8Y164V895Y / Carbachol; EC 1.14.13.39 / Nitric Oxide Synthase
  •  go-up   go-down


62. Lund JA, Wibe A, Sundstrom SH, Haaverstad R, Kaasa S, Myrvold HE: Anal carcinoma in mid-Norway 1970-2000. Acta Oncol; 2007;46(7):1019-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal carcinoma in mid-Norway 1970-2000.
  • The treatment of anal carcinoma changed from surgery to chemoradiotherapy 20-25 years ago.
  • The aim of this observational study was to compare surgery with chemoradiotherapy with regard to side effects, local recurrence and survival during and after the implementation of a new treatment policy for anal carcinoma.
  • The study includes all 111 patients with anal carcinoma diagnosed between 1970 and 2000 in mid-Norway.
  • Stage, age and treatment were all significant indicators of survival in uni- and multivariable analysis.
  • Late side effects were moderate after combined therapy; only one patient preferred getting a stoma due to radiation damage of the anal sphincter.
  • The change of strategy for anal cancer treatment from surgery to combined therapy has probably reduced local recurrence and improved survival.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma / therapy. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / mortality

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17882558.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  •  go-up   go-down


63. Deniaud-Alexandre E, Touboul E, Tiret E, Sezeur A, Hannoun L, Houry S, Huguet F, Pène F, Parc R, Schlienger M: [Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)]. Cancer Radiother; 2006 Dec;10(8):572-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)].
  • [Transliterated title] Carcinomes épidermoïdes du canal anal traités par association concomitante de radiothérapie et de chimiothérapie. Evaluation des résultats fonctionnels.
  • PURPOSE: To evaluate our results after radiation therapy and concomitant chemotherapy in terms of local control, survival and toxicity in patients with anal cancer.
  • The T-stage according to the 2001 UICC classification were: 2 T1, 26 T2, 25 T3, and 7 T4.
  • LC rate with a good anal function scoring (score 0 and 1) was 70%.
  • Among 43 pts who preserved their anus, 98% had a good anal function scoring.
  • Late severe complication was observed in 3 pts: 2 pts with painful necrosis of the anus requiring colostomy and 1 pt with grade 3 rectal bleeding.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / pathology. Antimetabolites, Antineoplastic / administration & dosage. Brachytherapy. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Follow-Up Studies. HIV Seropositivity. Humans. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17110148.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


64. Loredo-Pozos G, Chiquete E, Oceguera-Villanueva A, Panduro A, Siller-López F, Ramos-Márquez ME: Expression profile of BRCA1 and BRCA2 genes in premenopausal Mexican women with breast cancer: clinical and immunohistochemical correlates. Med Oncol; 2009;26(3):269-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profile of BRCA1 and BRCA2 genes in premenopausal Mexican women with breast cancer: clinical and immunohistochemical correlates.
  • Low BRCA1 gene expression is associated with increased invasiveness and influences the response of breast carcinoma (BC) to chemotherapeutics.
  • Women aged < or = 35 years (24%) had more family history of cervical cancer, stage III/IV disease, HER-2 positivity, and lower BRCA1 expression than older women (P < 0.05).
  • After multivariate analysis, only disease stage explained BRCA1 mRNA levels in the lowest quartile.
  • Low BRCA1 mRNA expression is associated mainly with younger ages and advanced clinical stage of premenopausal BC.


65. Ren N, Qin LX, Tu H, Liu YK, Zhang BH, Tang ZY: The prognostic value of circulating plasma DNA level and its allelic imbalance on chromosome 8p in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol; 2006 Jun;132(6):399-407
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic value of circulating plasma DNA level and its allelic imbalance on chromosome 8p in patients with hepatocellular carcinoma.
  • PURPOSE: We demonstrated that chromosome 8p deletion is associated with metastasis of human hepatocellular carcinoma (HCC).
  • RESULTS: The circulating plasma DNA level was found to closely associate with tumor size (P=0.008) and TNM stage (P=0.040), negatively associate with the 3-year disease-free survival (DFS) (P=0.017) and overall survival (OS) (P=0.001).
  • AI at D8S258 in plasma DNA was significantly correlated with tumor differentiation (P=0.050), TNM stage (P=0.010), and vascular invasion (P=0.023), negatively correlated with the 3-year DFS (P=0.005) and OS (P=0.036).
  • [MeSH-major] Allelic Imbalance. Carcinoma, Hepatocellular / diagnosis. Chromosomes, Human, Pair 8 / genetics. DNA, Neoplasm / blood. Liver Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Chromosome 8p.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1999 Jul;155(1):267-74 [10393858.001]
  • [Cites] Mol Diagn. 1997 Mar;2(1):3-10 [10462585.001]
  • [Cites] Gut. 2002 Apr;50(4):530-4 [11889075.001]
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5662-5 [10582679.001]
  • [Cites] C R Seances Soc Biol Fil. 1948 Feb;142(3-4):241-3 [18875018.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):367-70 [11809681.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Nov;26(3):253-7 [10502324.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):35-40 [11801538.001]
  • [Cites] Clin Exp Metastasis. 1999;17(6):471-9 [10763912.001]
  • [Cites] Genes Chromosomes Cancer. 1999 May;25(1):1-5 [10221333.001]
  • [Cites] Nature. 1953 Apr 25;171(4356):737-8 [13054692.001]
  • [Cites] Int J Cancer. 2003 Jun 20;105(3):361-70 [12704670.001]
  • [Cites] Lab Invest. 2000 Jul;80(7):1089-93 [10908154.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):578-84 [10080602.001]
  • [Cites] Cancer. 1990 Nov 15;66(10):2174-9 [2171748.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1047-52 [12631605.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4675-8 [11406535.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5723-6 [11479206.001]
  • [Cites] Anticancer Res. 2002 Jan-Feb;22(1A):421-5 [12017326.001]
  • [Cites] Int J Oncol. 2002 Jan;20(1):107-15 [11743649.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1579-82 [14571790.001]
  • [Cites] Br J Cancer. 2002 Dec 2;87(12):1449-53 [12454776.001]
  • [Cites] Oncogene. 1998 Sep 3;17(9):1185-8 [9764830.001]
  • [Cites] Transfusion. 2001 Feb;41(2):276-82 [11239235.001]
  • [Cites] Am J Pathol. 1997 Sep;151(3):753-9 [9284824.001]
  • [Cites] Mol Med. 1995 May;1(4):344-65 [8521292.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 4;91(15):1295-303 [10433618.001]
  • [Cites] World J Gastroenterol. 2001 Aug;7(4):445-54 [11819809.001]
  • [Cites] World J Gastroenterol. 2002 Oct;8(5):769-76 [12378613.001]
  • [Cites] Head Neck. 2002 Jun;24(6):591-6 [12112557.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Jul;31(3):221-7 [11391792.001]
  • [Cites] Int J Cancer. 2003 Jan 10;103(2):149-52 [12455027.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Oct;29(2):110-6 [10959090.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1805-11 [11078757.001]
  • [Cites] World J Gastroenterol. 2002 Apr;8(2):193-9 [11925590.001]
  • [Cites] Clin Chem. 2001 Sep;47(9):1607-13 [11514393.001]
  • [Cites] Cancer. 1999 Jan 15;85(2):447-52 [10023714.001]
  • [Cites] Hepatology. 1999 Oct;30(4):1027-36 [10498656.001]
  • [Cites] J Cancer Res Clin Oncol. 2001 Aug;127(8):482-8 [11501747.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3479-82 [11719392.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 May;129(5):279-86 [12734753.001]
  • [Cites] Int J Cancer. 1999 Sep 24;83(1):18-29 [10449602.001]
  • [Cites] Otolaryngol Head Neck Surg. 2001 Apr;124(4):451-5 [11283506.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10):2689-92 [10537330.001]
  • [Cites] Genes Chromosomes Cancer. 1996 Dec;17(4):260-8 [8946208.001]
  • [Cites] Br J Cancer. 2000 Jan;82(1):65-73 [10638968.001]
  • [Cites] N Engl J Med. 2004 Jun 10;350(24):2461-70 [15190138.001]
  • [Cites] Cancer Metastasis Rev. 1999;18(1):65-73 [10505546.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1022:17-24 [15251934.001]
  • [Cites] Cancer Res. 1977 Mar;37(3):646-50 [837366.001]
  • [Cites] Curr Med Chem. 2003 Apr;10(8):691-706 [12678787.001]
  • [Cites] Oncology. 1989;46(5):318-22 [2779946.001]
  • [Cites] J Hepatol. 2001 Jun;34(6):840-9 [11451167.001]
  • [Cites] Ann Clin Biochem. 2003 Mar;40(Pt 2):122-30 [12662399.001]
  • [Cites] Anal Biochem. 1999 Dec 1;276(1):59-64 [10585744.001]
  • [Cites] Int J Oncol. 1999 Mar;14(3):495-500 [10024682.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • (PMID = 16502316.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


66. Beretta G, Furlanetto S, Regazzoni L, Zarrella M, Facino RM: Quenching of alpha,beta-unsaturated aldehydes by green tea polyphenols: HPLC-ESI-MS/MS studies. J Pharm Biomed Anal; 2008 Nov 4;48(3):606-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HNE is the most abundant and genotoxic product of oxidation of dietary polyunsaturated fatty acids, and is believed to be involved in the early stage of colorectal carcinogenesis on account of its genotoxic potential.
  • These results suggest that EGCG and green tea extract, beside the proposed mechanisms of chemoprevention that target multiple cell-signaling pathways that control cell proliferation and apoptosis in cancer cells, can also prevent protein carbonylation in the tumor tissue environment, depending on the pH of the medium surrounding the tissue, the type of tumor, the stage of dysregulation of lipid peroxidation and, finally, the stage of carcinoma development.

  • Hazardous Substances Data Bank. Green tea .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18619756.001).
  • [ISSN] 0731-7085
  • [Journal-full-title] Journal of pharmaceutical and biomedical analysis
  • [ISO-abbreviation] J Pharm Biomed Anal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aldehydes; 0 / Flavonoids; 0 / Phenols; 0 / Polyphenols; 0 / Tea
  •  go-up   go-down


67. Rabbani AN, Zlotecki RA, Kirwan J, George TJ Jr, Morris CG, Rout WR, Mendenhall WM: Definitive radiotherapy for squamous cell carcinoma of the anal canal. Am J Clin Oncol; 2010 Feb;33(1):47-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Definitive radiotherapy for squamous cell carcinoma of the anal canal.
  • PURPOSE: To review the outcomes of definitive radiotherapy (RT) alone or combined with chemotherapy (CT) in the treatment of squamous cell carcinoma of the anal canal.
  • Distribution according to T stage was: T1, 11 (16%); T2, 29 (42%); T3, 21 (30%); and T4, 8 (12%).
  • Distribution according to N stage was: N0, 53 (77%); N1, 3 (4%); N2, 7 (10%); and N3, 6 (9%).
  • The 5-year cause-specific and overall survival rates were: stage I, 100% and 64%; stage II, 86% and 70%; stage III, 80% and 76%; and overall, 87% and 71%, respectively.
  • [MeSH-major] Anal Canal / radiation effects. Antineoplastic Agents / therapeutic use. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Neoplasm Recurrence, Local / diagnosis


68. Lingappa M, Song H, Thompson S, Bruchertseifer F, Morgenstern A, Sgouros G: Immunoliposomal delivery of 213Bi for alpha-emitter targeting of metastatic breast cancer. Cancer Res; 2010 Sep 01;70(17):6815-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoliposomal delivery of 213Bi for alpha-emitter targeting of metastatic breast cancer.
  • Current treatment for late-stage metastatic breast cancer is largely palliative. alpha-Particles are highly potent, short-range radiation emissions capable of sterilizing individual cells with one to three traversals of the cell nucleus.
  • Efficacy in a rat/neu transgenic mouse model of metastatic mammary carcinoma was investigated.
  • We have shown that the (213)Bi radiolabeled immunoliposomes are effective in treating early-stage micrometastases, giving median survival times similar to those obtained with antibody-mediated delivery of (213)Bi in this animal model.

  • Hazardous Substances Data Bank. BISMUTH, ELEMENTAL .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Biother Radiopharm. 2004 Dec;19(6):706-15 [15665617.001]
  • [Cites] Health Phys. 1960 Feb;2:225-38 [13818815.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11631-8 [16357174.001]
  • [Cites] Curr Pharm Des. 2006;12(36):4729-49 [17168775.001]
  • [Cites] Bioconjug Chem. 2007 Nov-Dec;18(6):2061-7 [17935286.001]
  • [Cites] Expert Opin Drug Deliv. 2008 Feb;5(2):189-204 [18248318.001]
  • [Cites] Cancer Biother Radiopharm. 2008 Feb;23(1):74-81 [18298331.001]
  • [Cites] Cancer Res. 2008 May 15;68(10):3873-80 [18483272.001]
  • [Cites] Clin Cancer Res. 2008 Oct 1;14(19):6116-24 [18829490.001]
  • [Cites] Cancer Res. 2009 Dec 1;69(23):8941-8 [19920193.001]
  • [Cites] J Nucl Med. 2010 Feb;51(2):311-28 [20080889.001]
  • [Cites] J Nucl Med. 1999 Nov;40(11):1935-46 [10565792.001]
  • [Cites] Pharmacol Rev. 1999 Dec;51(4):691-743 [10581328.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3569-76 [10910070.001]
  • [Cites] Pharm Res. 2002 Mar;19(3):265-9 [11934232.001]
  • [Cites] J Nucl Med. 2004 Feb;45(2):253-60 [14960644.001]
  • [Cites] Science. 2004 Mar 19;303(5665):1818-22 [15031496.001]
  • [Cites] Expert Opin Ther Targets. 2004 Aug;8(4):335-53 [15268628.001]
  • [Cites] Bioconjug Chem. 1992 Jul-Aug;3(4):342-5 [1390990.001]
  • [Cites] Cancer Res. 1993 Aug 15;53(16):3765-70 [8339289.001]
  • [Cites] Biochim Biophys Acta. 1994 Feb 23;1190(1):99-107 [8110825.001]
  • [Cites] Cancer Res. 1994 Jul 1;54(13):3352-6 [8012948.001]
  • [Cites] Nucl Med Biol. 1995 Apr;22(3):387-90 [7627155.001]
  • [Cites] J Nucl Med. 1995 Sep;36(9):1639-44 [7658225.001]
  • [Cites] J Leukoc Biol. 1996 Sep;60(3):337-44 [8830790.001]
  • [Cites] Biochemistry. 1997 Jan 7;36(1):66-75 [8993319.001]
  • [Cites] J Nucl Med. 1997 Mar;38(3):489-93 [9074545.001]
  • [Cites] Appl Radiat Isot. 1999 May;50(5):895-904 [10214708.001]
  • [Cites] Int J Pharm. 1999 Oct 15;188(1):87-95 [10528086.001]
  • [Cites] J Biol Chem. 1959 Mar;234(3):466-8 [13641241.001]
  • [Cites] Anal Chem. 2005 Oct 1;77(19):6288-91 [16194090.001]
  • (PMID = 20651254.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA113797; United States / NCI NIH HHS / CA / R01 CA113797-04; United States / NCI NIH HHS / CA / R01 CA187037
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoconjugates; 0 / Isothiocyanates; 0 / Liposomes; 0 / Radioisotopes; 142434-84-2 / N-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-N,N',N',N'',N''-pentaacetic acid; 7A314HQM0I / Pentetic Acid; EC 2.7.10.1 / Receptor, ErbB-2; U015TT5I8H / Bismuth
  • [Other-IDs] NLM/ NIHMS248891; NLM/ PMC2977986
  •  go-up   go-down


69. Jelski W, Mroczko B, Szmitkowski M: The diagnostic value of alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) measurement in the sera of colorectal cancer patients. Dig Dis Sci; 2010 Oct;55(10):2953-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnostic value of alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) measurement in the sera of colorectal cancer patients.
  • BACKGROUND: The activity of total alcohol dehydrogenase (ADH) and class I isoenzymes is significantly higher in colorectal cancer tissue than in healthy mucosa.
  • The activity of these enzymes in cancer cells is probably reflected in the sera and could thus be helpful for diagnosing colorectal cancer.
  • AIM: The aim of this study was to investigate a potential role of ADH and aldehyde dehydrogenase (ALDH) as tumor markers for colorectal cancer.
  • METHODS: Serum samples were taken from 182 patients with colorectal cancer before treatment and from 160 control subjects.
  • RESULTS: There was significant increase in the activity of ADH I isoenzyme and ADH total in the sera of colorectal cancer patients compared to the control.
  • The sensitivity and specificity of ADH I increased with the stage of the carcinoma.
  • CONCLUSION: The results suggest a potential role for ADH I as marker for colorectal cancer.
  • [MeSH-major] Alcohol Dehydrogenase / blood. Aldehyde Dehydrogenase / blood. Biomarkers / blood. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / metabolism. Isoenzymes / blood

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 1989 Oct 23;257(1):105-9 [2806555.001]
  • [Cites] Clin Chem. 1993 Nov;39(11 Pt 1):2298-304 [8222224.001]
  • [Cites] Clin Exp Med. 2006 Jun;6(2):89-93 [16820997.001]
  • [Cites] Anal Biochem. 1989 Apr;178(1):57-62 [2729580.001]
  • [Cites] Dig Dis Sci. 2004 Jun;49(6):977-81 [15309886.001]
  • [Cites] Clin Exp Med. 2007 Dec;7(4):154-7 [18188528.001]
  • [Cites] Anal Biochem. 1979 Oct 15;99(1):65-71 [231394.001]
  • [Cites] Dig Dis Sci. 2005 Jun;50(6):1019-24 [15986847.001]
  • [Cites] Hematol Oncol Clin North Am. 2002 Aug;16(4):775-810 [12418049.001]
  • [Cites] Digestion. 1996;57(2):105-8 [8785998.001]
  • [Cites] Clin Chem Lab Med. 2008;46(10):1423-8 [18844497.001]
  • [Cites] Clin Chim Acta. 2006 Sep;371(1-2):143-7 [16603145.001]
  • [Cites] Clin Chim Acta. 2007 May 1;380(1-2):208-12 [17368603.001]
  • [Cites] Alcohol Clin Exp Res. 1996 May;20(3):551-5 [8727253.001]
  • [Cites] Alcohol Clin Exp Res. 1996 Dec;20(9):1569-76 [8986205.001]
  • [Cites] Int J Colorectal Dis. 2007 Jan;22(1):33-8 [16520929.001]
  • [Cites] Clin Chem Lab Med. 2003 May;41(5):646-51 [12812262.001]
  • [Cites] BMJ. 2000 Feb 12;320(7232):424-7 [10669448.001]
  • (PMID = 20069455.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Isoenzymes; EC 1.1.1.1 / Alcohol Dehydrogenase; EC 1.2.1.3 / Aldehyde Dehydrogenase
  •  go-up   go-down


70. Oehler-Jänne C, Seifert B, Lütolf UM, Ciernik IF: Local tumor control and toxicity in HIV-associated anal carcinoma treated with radiotherapy in the era of antiretroviral therapy. Radiat Oncol; 2006;1:29
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local tumor control and toxicity in HIV-associated anal carcinoma treated with radiotherapy in the era of antiretroviral therapy.
  • PURPOSE: To investigate the outcome of HIV-seropositive patients under highly active antiretroviral treatment (HAART) with anal cancer treated with radiotherapy (RT) alone or in combination with standard chemotherapy (CT).
  • 10 TNM-stage and age matched HIV-seronegative patients (1992-2003) were compared with the 10 HIV-seropositive patients.
  • Pattern of care, local disease control (LC), overall survival (OS), cancer-specific survival (CSS), and toxicity were assessed.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Anus Neoplasms / virology. HIV Infections / complications. HIV Infections / drug therapy. Radiotherapy / methods


71. Ortholan C, Ramaioli A, Peiffert D, Lusinchi A, Romestaing P, Chauveinc L, Touboul E, Peignaux K, Bruna A, de La Roche G, Lagrange JL, Alzieu C, Gerard JP: Anal canal carcinoma: early-stage tumors &lt; or =10 mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy. Int J Radiat Oncol Biol Phys; 2005 Jun 1;62(2):479-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal canal carcinoma: early-stage tumors < or =10 mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy.
  • PURPOSE: To investigate the clinical history, management, and pattern of recurrence of very early-stage anal canal cancer in a French retrospective survey.
  • METHODS: The study group consisted of 69 patients with Stage Tis and T1 anal canal carcinoma < or =1 cm treated between 1990 and 2000 (12 were in situ, 57 invasive, 66 Stage N0, and 3 Stage N1).
  • Of the 69 patients, 66 received radiotherapy (RT) and 3 with in situ disease were treated by local excision alone without RT.
  • These small anal cancers could be treated by RT using a small volume and moderate dose (40-50 Gy for subclinical lesions and 50-60 Gy for T1).
  • [MeSH-major] Anus Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / physiology. Carcinoma in Situ / pathology. Carcinoma in Situ / radiotherapy. Carcinoma in Situ / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / radiotherapy. Carcinoma, Transitional Cell / surgery. Chi-Square Distribution. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15890590.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Oono Y, Fu K, Nakamura H, Iriguchi Y, Yamamura A, Kishi D, Oda J, Ikematsu H, Mizutani M, Takayanagi S, Tomino Y: Narrowband imaging colonoscopy with a transparent hood for diagnosis of a squamous cell carcinoma in situ in the anal canal. Endoscopy; 2010;42 Suppl 2:E183-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Narrowband imaging colonoscopy with a transparent hood for diagnosis of a squamous cell carcinoma in situ in the anal canal.
  • [MeSH-major] Anus Neoplasms / diagnosis. Carcinoma, Squamous Cell / diagnosis. Colonoscopy / methods


73. Kurt M, Ozkan L, Ercan I, Kahraman S, Zorluoglu A, Gurel S, Memik F, Engin K: Preoperative chemoradiotherapy in patients with locally advanced rectal cancer. Hepatogastroenterology; 2005 Jul-Aug;52(64):1095-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative chemoradiotherapy in patients with locally advanced rectal cancer.
  • BACKGROUND/AIMS: To determine the percentage of responders and the resectability rate for patients with locally advanced carcinoma of the rectum treated by infusional 5-fluorouracil chemotherapy and pelvic radiation.
  • METHODOLOGY: Twenty-four patients with a diagnosis of locally advanced unresectable rectal cancer received preoperative 5-fluorouracil by intravenous infusion at the dose of 250-300mg/m2/day concurrent with pelvic radiation (median 50.4 Gy/28 fractions).
  • Surgery was performed with a mean delay of 15 days after completion of irradiation and included 11 abdominoperineal resections and five anal sphincter-preserving procedures.
  • There was a significant difference in the rate of local control based on the distance of the tumor from the anal verge (>5.4cm; p=0.046).
  • With metastasis-free survival as the endpoint, only stage (p=0.027) was a statistically significant prognostic factor.
  • CONCLUSIONS: The favorable influence of higher doses of preoperative radiotherapy on pathologic stage has been observed.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16001638.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


74. Sameer AS, Chowdri NA, Syeed N, Banday MZ, Shah ZA, Siddiqi MA: SMAD4--molecular gladiator of the TGF-beta signaling is trampled upon by mutational insufficiency in colorectal carcinoma of Kashmiri population: an analysis with relation to KRAS proto-oncogene. BMC Cancer; 2010;10:300
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SMAD4--molecular gladiator of the TGF-beta signaling is trampled upon by mutational insufficiency in colorectal carcinoma of Kashmiri population: an analysis with relation to KRAS proto-oncogene.
  • BACKGROUND: The development and progression of colorectal cancer has been extensively studied and the genes responsible have been well characterized.
  • CONCLUSION: Our study suggests that SMAD4 gene aberrations are the common event in CRC development but play a differential role in the progression of CRC in higher tumor grade (C+D) and its association with the KRAS mutant status suggest that these two molecules together are responsible for the progression of the tumor to higher/advanced stage.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Squamous Cell / genetics. Colorectal Neoplasms / genetics. Mutation. Proto-Oncogene Proteins / genetics. Signal Transduction. Smad4 Protein / genetics. Transforming Growth Factor beta / metabolism. ras Proteins / genetics